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Abstract 3
Abstract
The effect of uncertainty in biopharmaceutical manufacturing can be a barrier to ro-
bust, scalable process design. The ideal is for a process in development to complete
technology transfer to full scale manufacturing with no redevelopment costs or sur-
prises. Essential to achieving this is a systematic method for analysing large complex
datasets and extracting critical combinations of fluctuations that lead to product loss
and scheduling delays.
This thesis describes a dynamic database-driven decision-support tool to facili-
tate such efforts and identify robust optimal purification strategies to match the high
productivity cell cultures whilst coping with uncertainties. The benefits of a database-
driven approach using MySQL (MySQL AB, Uppsala, Sweden) are harnessed to cap-
ture the process, business and risk features of multiple biopharmaceutical purification
sequences in a multi-product facility and better manage the large datasets required for
multiple processes, uncertainty analysis and optimisation.
Principal component analysis combined with clustering algorithms are used to
analyse the complex datasets from complete batch processes for biopharmaceuticals.
The challenge of visualising the multidimensional nature of the dataset was addressed
using hierarchical and k-means clustering as well as parallel co-ordinate plots to help
identify process fingerprints and characteristics of clusters leading to facility fit issues.
Industrially-relevant case studies are presented that focus on tech transfer challenges
for therapeutic antibodies moving from early phase to late phase clinical trials.
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Chapter 1
Introduction
1.1 Drug Development
In biopharmaceutical manufacturing the aim is to deliver a product to the market in the
shortest available time with a robust, economically viable process. In order to reach the
market there are several stages of development, each with specific challenges. These
stages are summarised in figure 1.1. Figure 1.1 also shows the typical scale of operation
highlighting one of the key process development challenges of producing a scalable
process at 10L which will perform at 10,000L scale.
Figure 1.1: Stages of drug development and associated scale of operation. Scale
of operation refers to the typical volume prior to purification.
Up to the point of late phase clinical manufacture, it is common for minor process
changes which may also be referred to as process intensification, to be made to improve
robustness and scalability. As the process moves through the development pathway,
the regulatory burden increases and the justification for changes as having no impact
on the product become more stringent. By the time of commercial manufacture the
process is in essence locked and any changes must be fully justified to the regulators
and supported with costly experimental studies.
Development of a biopharmaceutical is currently expected to take approximately
6-7 years. (Rosenberg, 2000) Over this time there is significant risk associated with
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each stage in the process. (Zabriskie and Sofer, 2000) Figures for the average per-
centages of biopharmaceuticals which pass the stages of clinical trials validation are
reported as; 15% of products pass phase 1, 40% for phase 2 and 80% for phase 3. This
results in less than 5% of the products entering clinical trials making it to market.
Over the past 15-20 years, the cost to develop biopharmaceuticals has seen a sig-
nificant rise. Figures quoted by Tufts in a report of Nov 2005 (Tufts, 2005) placed
the average cost of developing a biopharmaceutical in 1987 at US$231m, this figure
rose to US$802m in 2000. Generally, this rise is attributed to more rigorous regulatory
requirements, specifically longer clinical trials.
The emphasis on clinical trials may suggest that process development timelines do
not lie on the critical path to market. Broadly speaking this is the case, however one
key trend in the industry is the rise of small companies which outsource development
and manufacture of their portfolio to contract manufacturers as opposed to cash rich
large pharmaceutical companies that maintain the capacity in-house. For these small
companies the aim is to demonstrate efficacy such that the process can be sold and
taken to market by larger pharmaceutical companies. For these companies the end of
the process is not commercialisation, it is early phase clinical trials and the timelines
and cost for development are therefore often compressed.
Each stage in the drug development pathway presents a particular tech transfer
challenge. The development of platform technologies and processes can provide a
solid basis for process development efforts. An appropriately scoped platform can
ensure that the process developed within its bounds does, at a high level, fit to the
target facilities. Even with a solid platform process however, there are still process
specific fit challenges that will arise.
This thesis is aimed at the development of a simulation framework to address some
of the challenges that occur upon scale up from the process development scale through
to commercial manufacture. With the knowledge gained at each stage of development,
the aim is to simulate the performance at latter stages to target process intensification
efforts.
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1.2 Platforms Processes and Technologies
The development of platform processes reduces the potential for major fit issues and act
to target development efforts inline with the capability of commercial facilities. This
section coverers some of the major platform technologies in used in the purification
of mAbs from mammalian cell lines. (Fahrner et al., 2001; Shukla et al., 2007) Any
simulation engine developed to investigate mAb production processes must be capable
of simulating the process types and unit operations outlined in this section.
1.2.1 Platform Process Paradigms
Elements of a typical platform process can be summarised as follows:
• Product capture is typically carried out using affinity-based chromatographic
separation.
• Virus inactivation is generally achieved through either solvent/detergent treat-
ment or more commonly low pH inactivation.
• Ultrafiltration and diafiltration (UFDF) is used to to condition the product
stream by changing the concentration through ultrafiltration and the buffer com-
position through diafiltration to be optimal for subsequent polishing steps.
• Polishing or further purification or is then achieved through a further sequence
of chromatography operations with intermediate ultrafiltration and diafiltration
(UF/DF) steps for buffer exchange and concentration.
• Nano-filtration is employed for the reduction of viruses and along with virus
inactivation forms the two orthogonal virus reduction steps as required by regu-
latory authorities. (ICH, 1999)
• Final bulk product formulation is achieved by ultrafiltration / diafiltration, to
adjust to the final concentration and transition the product into the final formula-
tion buffer.
More detail on each of these steps is outlined below.
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1.2.1.1 Product Capture
The promise of >90% purity and high yields in a single step has led to protein A
becoming the dominant capture technology (Hober et al., 2007; Fahrner et al., 2001;
Shukla et al., 2007). This power does however come at a price and protein A affinity
resins may account for up to 25% of the batch cost. (Gu¨lich et al., 2000)
Protein A affinity chromatography is operated in bind and elute mode with the
protein A ligand binding the Fragment Crystallisable (Fc) region which is common to
all mAbs. As such this one technology can be used with a generally high degrees of
success for most mAb processes. (Vunnum et al., 2008) Once bound to the column, the
column is washed using a number of wash buffers to remove non-specifically bound
components such as DNA, host cell proteins and cell culture media components. After
washing, the product is eluted by using a low pH buffer which causes the product to
dissociate from the resin and flow off the column. Once the product is eluted the column
is stripped of more tightly bound proteins at an even lower pH before being regenerated
and cleaned using chaotropic agents such as guanidine or urea, (Girot et al., 1990) or
for alkali stable resins, sodium hydroxide is used. (Hahn et al., 2006)
Once regenerated the resin may be reused to form part of multi-cycle runs. De-
pending on the cleaning conditions resins may be used for in excess of 100 cycles (Hale
et al., 1994) meaning that for commercial manufacture the potential exists for the high
cost of the resin to be amortised across a large number of batches. For clinical trails
manufacture where the campaigns are generally smaller the cost advantage of multi-
cycling is smaller as the resin life is often not reached.
Scalability and Facility Fit Considerations: Chromatography steps are scaled by
maintaining constant residence time of the product and buffers as they flow through
the column as well as a constant column resin loading capacity. Loading capacity is
defined as grams of product per litre of resin (gproduct/Lresin). The most common and
simplest strategy to maintain residence time is to use constant bed height and linear
flow rate across all scales. The column step is then scaled by changing the diameter
of the column and the number of cycles run. This leads to a trade off between run-
ning large numbers of cycles in a small column or few cycles in a larger column. This
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equates to a cost vs. time optimisation challenge. Facility fit considerations for chro-
matography are focused on the maximum achievable flow rates and column diameters
at scale as well as schedule constraints. The relative complexity of the step compared
to other chromatography operations with respect to wash buffers means that the buffer
demands for protein A operations can be high and may approach the limits of buffer
storage.
1.2.1.2 Ultrafiltration / Diafiltration and Final Formulation
UFDF steps are designed to concentrate the product stream and for buffer exchange.
The majority of platform processes will have a UFDF step after the product capture
step and possibly between polishing steps depending on the order and selection of chro-
matography steps used. It is possible to optimise the buffering systems of the polishing
steps such that only conductivity or pH adjustments by titration are required to condi-
tion the process steam for loading. The majority of mAb processes will have a UFDF
step at the end of the process to formulate the product into its final formulation buffer
and concentration. (Teeters et al., 2011)
The primary technology of UFDF steps for the purification of mAbs is tangential
flow filtration (TFF). In TFF the product is re-circulated around one side of a membrane
with a molecular weight cut off smaller than the antibody (usually 30 - 50kDa), a trans-
membrane pressure is applied across the membrane which forces the buffer to permeate
through the membrane whist the product is retained. In ultrafiltration mode the buffer
permeates through the membrane and the volume of the retained product stream drops,
thus increasing the product concentration. In diafiltration mode, the buffer into which
the product is to be exchanged is continually pumped into the retained product stream
such that the product concentration is maintained. The result is that over time the con-
centration of buffer components will be exchanged. The volume of the process stream
prior to the start of diafiltration is referred to as the diafiltration volume (DV). In order
to achieve near total buffer exchange, 8-10 DVs of diafiltration buffer must be used.
(Teeters et al., 2011) Total buffer exchange is required for final formulation operations
however for product conditioning it is normally acceptable for a lower number of DVs
to be used as long as pH and conductivity specifications are met.
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Scalability and Facility Fit Considerations: There are various methods to scale
UFDF operations. Principle amongst these is to use constant trans-membrane pres-
sure across all scales, the area of the filter can then be determined based on data for
the permeate flux decay rate and scheduling constraints. Facility fit considerations for
scale up are the maximum installable membrane area which will determine the mini-
mum processing time.
1.2.1.3 Virus Inactivation and Nano-filtration
Two orthogonal virus reduction and removal steps must be built into any mAb process
in order to satisfy regulatory requirements. (ICH, 1999) The term orthogonal means
that these two steps must use different mechanisms for virus reduction and inactivation.
In most cases this takes the form of a chemical inactivation step and a separate normal
flow nano-filtration step.
Chemical inactivation works by disrupting the proteins and or genome of viruses.
Numerous methods exist, such a treatment with solvents, detergents, heat or UV. As
mAbs are generally tolerant to low pH environments the most common method for
virus inactivation is titration with acid to a low pH. This also fits well with the use of
protein A affinity capture as the product often elutes at a low pH and requires only
minor adjustment to be within the inactivation range of between pH3.0 and 4.0 and is
depended on product stability. (Vunnum et al., 2008) Once at the inactivation pH the
product is held for between 30min and 1h depending on the pH used (Brorson et al.,
2003) prior to adjusting to a neutral pH to improve product stability prior to forward
processing.
Nano-filtration is almost exclusively used as the second orthogonal virus removal
step in mAb production. (Zhou et al., 2008) Key to its success is it’s reliability and
relative simplicity as a step. Nano-filtration steps are normally operated at constant
pressure and experience a flux decay as the filter fouls. A number of nano-filtration
products are available and due to the high cost of the membranes the focus for suppliers
is on increased capacity (i.e reduced flux decay). Nano-filtration steps are generally
placed towards the end of the process, often immediately prior to final formulation,
where the volumes are smaller and consequently the filter area is minimised.
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Other technologies such as depth filtration and charged membrane chromatog-
raphy have been documented for use as dedicated virus removal steps however their
adoption within platform processes for this use is still not widespread. (Zhou et al.,
2008)
Scalability and Facility Fit Considerations: Virus inactivation only requires a mixing
vessel which would typically be the protein A eluate pool tank and as such there are
no step specific scale up issues. Nano-filtration is scaled by maintaining consistent
loading of product volume per area of membrane referred to as the filter the capacity
and measured in l/m2. Facility fit concerns will be around maximum installable area.
Operationally an additional constraint of processing time may also be applied to reduce
exposure to bioburden as nano-filtration is not considered a sterile processing step.
1.2.1.4 Polishing
Polishing refers to one or a sequence of multiple chromatography steps that are de-
signed to remove those impurities which are present after product capture. These
impurities include process related impurities such as host cell proteins (HCP), DNA,
non-specifically bound cell culture components from the capture step, endotoxin and
product related impurities such as aggregates, fragments and modified or malformed
product species. The capture step may also introduce impurities in the form of leached
protein A ligand which must be removed. (Carter-Franklin et al., 2007) The polishing
steps also have an associated virus removal capability which is added to that of the
virus inactivation and the nano-filtration to add to the overall virus reduction capability
of the process.
The most common technologies employed during polishing are cation exchange
chromatography (CEX), anion exchange chromatography (AEX), hydrophobic interac-
tion chromatography (HIC) and hydroxyapatite (HA).
Anion exchange (AEX) uses charge to separate impurities. In flow through mode the
pH of the buffer is adjusted to below the isoelectric point (pI) of mAbs of between
pH6.1 and 8.5. In this mode the mAb flows through the column and negatively charged
impurities bind to the column. Operation above the pI means that the mAb will bind
to the column and the impurities will flow through to waste. Given the high pI of
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antibodies operation in flow through mode is more common. In this mode impurities
such as DNA, HCP and endotoxin are reduced. (Curtis et al., 2003)
Cation exchange (CEX) is used for the reduction of HCP and DNA. (Tugcu et al.,
2008) For cation exchange the relation to pI is reversed relative to AEX, as such the
common mode of operation is bind and elute, where the product binds to the resin and
the impurities are allowed to flow through. Cutting of the elution peak can also act to
remove aggregates on some CEX steps as elution conditions can be adjusted such that
they elute at a different rate than the product. (Aldington and Bonnerjea, 2007)
Hydroxyapetite (HA) is particularly used for the clearance of HCP and aggregates.
Aggregates may be present from the beginning of the process as they often have intact
Fc regions and so co-purify with the monomer on the capture step. Aggregates may also
be generated during the process through a variety of mechanisms such as concentration
dependent aggregation during UFDF steps. (Wang, 2005)
Hydrophobic interaction chromatography (HIC) can also be used for the reduction
of HCP, DNA, endotoxin and aggregates. (Aldington and Bonnerjea, 2007) In this step
high salt conditions are used to promote binding of the product and elution is achieved
using a low salt elution buffer. The often high salt concentration required for binding
can result in the precipitation of some mAbs so may limit the application of HIC as a
platform technology.
Scalability and Facility Fit Considerations: Polishing steps are chromatography
based therefore the scalability is the same as that for the product capture step. There
may however be additional facility fit concerns regarding elution volumes, specifically
when steps are operated in flow through elution where the degree of variability may be
higher due to the likelihood of tailing elution peaks.
1.2.2 Other Platform Technologies
A presentation given by Martin Wrankmore of Lonza Biologics talked about the effects
disposables have had on operations at Lonza. (Wrankmore, 2005) The presentation
highlighted the key advantages of disposables technology which include:
• Greater flexibility to adapt to changes in demand generated by increases in prod-
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uct concentrations from cell culture processes. i.e greater buffer demands, larger
eluates from columns.
• Ability to simplify processes.
• Significant reduction in on-site preparation work, i.e Clean in Place (CIP)/ Steam
in place (SIP)
• Reduced reliance on on-site utilities.
• More flexibility.
• Reduced risk of cross contamination.
The presentation goes on to talk about increased challenges that are presented by
the development of consumables such as balancing the cost of consumables against
costs savings through reduced time and resource demands. The cost aspect has been
discussed in various articles. An article in Bioprocess International talks about the
design of a concept facility. (Sinclair and Monge, 2002) The facility proposed was de-
signed to take full advantage of disposable technology in all areas of the process. In
terms of economics the initial capital outlay for this concept facility is expected to be up
to 41% lower, (reduced from £26.3m to £15.4m), than a similar non-disposables based
facility. Notable savings predicted by Sinclair are seen in areas such as buffer prepa-
ration, harvest, process utilities, solution handling, electrical power and validation. In
each of these areas the concept facility is predicted to reduce capital costs by between
66-93%. The only notable area where costs are predicted to increase is in the fitting
out of clean-rooms which sees a 26% increase. The reason for this increase is not dis-
cussed. A cost of goods analysis carried out by the same authors (Sinclair and Monge,
2005) stated that a traditional stainless steal based facility, producing 15-16kg per an-
num of a mAb, could see a cost of goods saving of 8% if retrofitted to take advantage
of disposable technology.
1.3 Bioprocess Modelling
Bioprocess modelling has been employed to support decision making in biopharma-
ceutical manufacturing in a variety of areas. Many of these models utilise simulation
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packages such as Extend (Imagine That! Inc. San Jose, USA), G2 (Gensym Corp.
TX, USA.) (Farid et al., 2007) or Aspen Batch (Aspen Technology Inc. MA, USA.) or
are mathematical, where the performance of processes is calculated using differential
equations. (Groep et al., 2000) The latter has seen limited success in the modelling of
biopharmaceutical processes due in part to the high degree of complexity and uncer-
tainty inherent in biological systems.
Applications such as Excel (Microsoft Inc. WA, USA.) and Superpro Designer
(Intelligen Inc. NJ USA) are commonly used to carry out investigations into facility
throughput, utility sizing and capital cost estimations. As static models, these tools are
limited in their ability to take into account the effects of dynamic factors such as re-
source and utility constraints.(Gosling, 2005) In order to provide a more complete anal-
ysis, tools must be able to account for those parameters which are time sensitive. This
is especially crucial when considering that two key parameters of interest are process
time and cost. With the simplified assumption that any amount of monoclonal antibody
(mAb) can be captured from any scale of process given sufficient time, capturing and
investigating the trade-offs requires an accurate calculation of both elements.
Previous models have followed common trends in structure and have been con-
structed using simulation engines such as Extend and a combination of spreadsheets
and custom user interfaces to manage the flow and storage of data. (Chhatre et al.,
2007) Additional graphical output has also been accomplished by linking the Excel
spreadsheets to MATLAB (The Mathworks Inc. MA, USA). (Chhatre et al., 2006)
Combining multiple applications in a single framework has the advantage of being
able to account for the weaknesses of one application with the strengths of another.
Whilst Chhatre et al. demonstrated this advantage, the degree of integration between
the components of the framework varied as did the methods for transferring data. Data
connectors such as those utilising open database connectivity (ODBC) can be used to
link the various elements of the framework. ODBC is an application and platform inde-
pendent application programming interface that enables a wide array of software tools
to exchange data using standardised methods. By utilising ODBC for data exchange the
elements of the simulation framework become compatible with a huge array of tools
ranging from statistical, graphical and data storage applications.
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Many of the existing approaches rely on prior knowledge of the factors to be in-
vestigated with a view to creating a model specific to the task. (Chhatre et al., 2007;
Farid et al., 2005b; Groep et al., 2000) To provide a framework that can handle dif-
ferent processes simultaneously, enable rapid reconfiguration with minimal effort and
have the flexibility to provide data for any number of process development questions
to a user with minimal modelling experience a more flexible approach is needed. In
addition to a flexible simulation engine, there is also the need for a data structure which
allows for the definition of a process and facility whilst remaining flexible enough to be
adaptable to scale. Previous research has described a hierarchical approach to structur-
ing bioprocess models (Farid et al., 2005b), this approach could serve as the foundation
to aid in the creation of standardised models and is of particular interest in developing a
structure for data storage which can be shared between models constructed on different
platforms by different developers.
Uncertainty is inherent with all biological processes, the risk of contamination of
cell culture, variability in product titres or failure of equipment can impact on pro-
cess design. Outside the process the possibility of products failing in clinical trials
or changes in market demand can affect the amount of product required and whether
processes will even appear on the manufacturing schedule. Monte Carlo simulations
have been used to generate data on the effects of risk and how different processing
options are compared (Lim et al., 2006). As alluded to earlier, the amount of data
generated when carrying out Monte Carlo simulation is significantly higher than from
deterministic models. Arriving at an optimum configuration will require the simulation
framework to assess potentially thousands of options, this must be done rapidly and
automatically.
1.4 Current Modelling Practices
1.4.1 Financial Models
Most companies will at some point attempt to produce financial model to predict costs
or to collate information to calculate company matrices such as Cost of Goods, Internal
Rate of Return, NPV or simple cash flow analyses. Most often these are static models
built in Excel.(Gosling, 2005) The products and use of these models is discussed below.
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1.4.1.1 Cost of Goods
Cost of goods (COG) analyses are used to provide a standard metric for manufactur-
ing costs. In the biopharmaceutical industry, COG is generally quoted as /g. In the
manufacture of any pharmaceutical it is always advantageous to have the lowest possi-
ble cost of goods. For this reason, COG is often one of the factors used to assess the
impact of process changes. Pharmaceutical processes are complex and the calculation
of cost of goods requires significant amounts of data, data which is not always readily
available, even more difficult is the accurate calculation of COG in advance of product
manufacture. A common approach to prediction of COG is to use factors to calculate
indirect costs based on direct costs. An example of a direct cost would be raw ma-
terial purchasing costs, this figure is usually readily available. More complex are the
additional costs which that raw material accumulates by it being stored in warehouses
or cooled. Factors can be used to account for these indirect costs. Farid et al. (2000);
Sinnot (1993)
1.4.1.2 Project Feasibility
Many financial models are used in an attempt to assess the feasibility of a project before
it is executed, or to compare different projects that may be proposed to solve a similar
problem. One of the most common analysis is the discounted cash flow, which is
used to calculate the Net Present Value of a project (NPV). (Novais et al., 2001) NPV
calculations are useful for rapid analysis for projects however the accuracy of these
calculations are limited as NPV is reliant on a discount factor which can be in itself
difficult to determine accurately. (Pandey, 2003)
1.4.2 Process Models
Process models are those models which are designed for analysis of processes either
in part, such as in unit operation models, or as a whole. (Gosling, 2005) In process
modelling the aim is to mimic the operation in the real world by using mathematical
formulae and logical programming. Key concepts and approaches in process modelling
are discussed below.
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1.4.2.1 Single Unit Operation Models
Computer models can be produced to predict the performance of single unit operations
such a centrifugation. (Varga et al., 2001) In these sorts of models differential equations
are generated to account for the changes in the variables over time. (Wai et al., 1996)
Once derived, usually based on experimental results, the equations are entered into a
mathematical modelling program such as Matlab where the values are calculated and
graphical outputs are generated. Models such as these are generally accurate within a
reasonable range however they are often quite specific, not only to unit operations, but
to individual models of equipment. (Gosling, 2005) This specificity makes these types
of models less ideal for entire process models on which to base management decisions.
1.4.2.2 Discrete Event Simulation
A model is a computer representation of a representation of a system or process, a
simulation is a model that accounts for the changes that occur within the system or
process over time. Most simulations fall into two categories, continuous or discrete
event. (Carson, 2005) Discrete event simulations differ from continuous in that discrete
event models only calculate the state of the system at certain defined points in time,
termed events. In continuous models the state of the system is defined by differential
equations which alter continually with respect to time. (Carson, 1993)
When modelling industrial processes discrete event simulation is generally the
preferred method as continuous simulations rely on equations which are not always
available.
1.4.2.3 Resource Allocation
In the real world tasks within a manufacturing process are constrained by resources and
it is often resources shared between multiple processes that increase the complexity of
a system and drive the need for simulation. (Law and Haider, 1989; Gosling, 2005)
All discrete event simulation platforms provide methods for accounting of resources.
As in the real world, resources will impact on the simulation by delaying or stopping
events from occurring. When building a simulation it is critical to identify the resources
present in a system and how they can effect the system
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In many industrial processes, the pharmaceutical industry being no exception, the
availability of resources can have a profound effect on the schedule of a process. At
the same time many of the resources such as raw materials and equipment are high cost
items and over availability can have significant negative effects on the cost of goods.
Simulation provides a tool where strategies to maximise the efficiency of resource us-
age can be quickly developed and tested. (Gosling, 2005)
1.4.2.4 Hierarchical Approach
In order to improve and perhaps begin to standardise the creation of process models,
hierarchical programming provides a major design methodology in the creation of sim-
ulations; it looks at the process in a series of levels of increasing complexity. (Lim et al.,
2004) By taking this approach and utilising the correct model building environment it
is possible to take an evolutionary approach to building simulations. Each layer in the
hierarchy can be built onto the next as new levels are developed, the model becomes
increasingly more complex, and more accurate at representing the system. By taking
this approach, the model begins to function and can be run and tested very early on in
the development process.
	  
Figure 1.2: An example of an hierarchical framework to accommodate pharma-
ceutical manufacturing Lim et al. (2004)
There is a further level of complexity that is not represented in Figure 1.2, this level
has been termed manufacturing phases (Farid et al., 2000) and represents the subtasks
that make up each unit operation.
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1.5 Simulation Packages
There are currently a number of packages on the market available for the modelling of
entire pharmaceutical processes.(Gosling, 2005) These include:
• SuperPro Designer developed by Intelligen Inc.
• Aspen Batch developed by Aspen Technology Inc.
• Extend developed by Imagine That inc.
Some analysis can also be carried out in Microsoft Excel.
Both SuperPro and Aspen Batch provide the user with a bank of unit operations
that can be used to build up a process. In both cases information about these operations
are stored in libraries that can expanded by the users own data. With differing degrees
of accuracy, both programs are also able to predict the effects of scale-up. The graphical
user interface of SuperPro provides increased usability over Aspen Batch’s command
line based structure. Both programs provide scheduling information by considering the
availability of resources. (Shanklin et al., 2001; Gosling, 2005)
Extend is a somewhat different package. Instead of having a bank of unit opera-
tions, Extend has a library of functions that can be used to build unit operations from
scratch. Essentially this means that the user can make the model as simple or complex,
as required. This flexibility also has disadvantages in that the model build process in
Extend is more complex and time consuming. As with SuperPro, Extend provides a
graphical user interface (GUI), greatly adding to it’s usability, in addition to the GUI,
Extend also provides the ability to modify the blocks in the simulation at the program-
ming code level. The language used is ModL, a variant of C making it relatively easy
to learn if required. (Krahl, 2002)
1.6 Managing Uncertainty
Many traditional approaches to assessing or predicting the performance of processing
strategies have relied on physical metrics; such as cell culture titre, percentage recovery
and batch times, and financial metrics such as cost and NPV. Although these can be
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good indicators, they do not provide the whole picture. Additional methods have been
proposed to provide decision-makers with more information. (Lim et al., 2005) Of
particular interest are the methods used to account for and quantify uncertainty. This
section discusses some of the proposed methods and how they may be incorporated
into existing methods.
1.6.0.5 Monte Carlo
Monte Carlo simulations are used to account for and assess the impact of risk on a
system. The Monte Carlo approach works by understanding that certain parameters
of a system are not fixed and are subject to a degree of variability. In many cases,
although variable, these parameters are not chaotic and instead the variability can be
accurately approximated using probability distributions. (Lim et al., 2005) Monte Carlo
functionality will greatly increase the run time of the process due to the large number
of iterations that are required to produce an accurate outcome. (Farid et al., 2005a)
Several applications exist which give MS Excel Monte Carlo functionality, these in-
clude @RISK (Palisade Corporation, Newfield, NY) and Crystal Ball (Decisioneering,
London, England). It is also possible to build Monte Carlo functionality into some
modelling environments such as Extend. (Curry, 2006)
1.6.0.6 Risk Adjusted Values
Another method has been demonstrated where values are adjusted based on their level
of risk, an example would be risk adjusted net present value (rNPV). (Stewart et al.,
2001) In general, NPV is calculated in the assumption that the project will be a suc-
cess, this means that a high NPV on its own is meaningless if the chance of success is
minimal, rNPV attempts to combine the metrics of Cost, Time and Risk into a single
factor. The equation used for the risk adjustment of any value is shown in equation 1.1.
rV = PR0 −
n∑
i=0
Ci
R0
Ri
(1.1)
Where: rV = Risk Adjusted Value, P = Payoff, R0 = Current Risk Ci = Associated
Cost, Ri = Risk associated with event i.
By adjusting the discounted cash flow throughout the project and carrying out a
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standard NPV calculation the rNPV can be produced. This is a quick simple way to
account for risk in financial factors within a project.
1.6.0.7 Decision Trees
For more complex series of events where there are multiple outcome for various situ-
ations decision trees can be constructed. A decision tree is a network of nodes, where
each node has a single input with multiple outputs. The probabilities are assigned to
each output where the sum of all output probabilities for each node is 1. Each output
can also have a cost or revenue associated with it. Decision trees can be analysed using
Monte Carlo simulations. (Critchfield and Willard, 1986)
1.7 Multivariate Statistical Techniques
Multivariate analysis (MVA) techniques such as PCA have been used in a range of
biotechnology applications. These include the use of PCA score plots to identify outlier
batches across vaccine production runs. (Thomassen YE, 2010)
Rapid identification of outliers is facilitated when a large number of process vari-
ables across multiple batches can be reduced to a plot of two principal components
that capture adequate variance in the data; observations outside a defined confidence
interval are considered outliers. PCA score plots combined with loading plots have
been used to assess process comparability for cell culture runs across different scales
of production. (Kirdar AO, 2007)
As well as looking at a wide array of process variables, PCA has been used to
reduce the dimensionality of complex and unwieldy datasets such as those generated
by near-infrared spectral analysis and chromatograms. This approach has been adopted
to analyse the near-infrared spectra of multiple raw material lots so as to understand the
impact of raw material variability captured by the spectra on cell culture performance.
(Lee HW, 2012; Kirdar AO, 2010)
On the downstream front, PCA has been used to analyse the impact of chromatog-
raphy operating conditions and scales on chromatogram profiles as well as to gener-
ate predictive models for chromatographic separations.(Pate ME, 2004; Malmquist G,
1994; Larson TM, 2003; Edwards-Parton S, 2008; Hou Y, 2011)
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Most works on MVA utilise historical datasets. However, the nature of tech trans-
fer activities where a single batch is usually run to identify facility fit issues and resolve
them before further batches are operated means that such datasets do not exist for this
problem. However, companies with experience in tech transfer activities can identify
typical process fluctuations seen from the expected base case performance. Monte
Carlo simulation has been used increasingly in various bioprocessing examples such as
process economics studies to capture the impact of common manufacturing uncertain-
ties such as yields and batch failures on cost metrics. (Farid et al., 2005b,a; Lim et al.,
2005, 2006; Pollock J, 2013)
Other applications include fermentation kinetic modelling studies where the im-
pact of uncertain model parameters on outputs such as biomass generation are ac-
counted for (Sin G, 2009) and portfolio management and capacity planning models
where reward-risk characteristics are generated given key technical, clinical, and com-
mercial uncertainties. (George and Farid, 2008; Rajapakse et al., 2005)
1.8 Research Focus
This work in this thesis focuses on the capture and purification operation steps which
will for the remainder be referred to as downstream processing (DSP). These DSP
operations receive material from upstream processing (USP) at a frequency which is
determined by the number of reactors and the cell culture time. This frequency in
turn determines the DSP slot length. For companies such as contract manufacturers,
a key aim during process development is to size equipment to meet the slot length
at minimum cost to ensure that DSP operations do not become the bottleneck in the
production schedule.
Achieving the optimal trade-off between processing time and cost is a complex
problem. As well as the core process operations, as discussed above, there are many
ancillary operations which must be taken into account. These operations include the
preparation of process buffers and the cleaning and sterilisation of equipment. Both
core and ancillary operations interact through a shared set of resources. Equipment
resources include chromatography columns and rigs, UF/DF skids as well as hold and
process vessels. Material resources include disposable bags, chromatography resins,
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filter cartridges, buffer reagents and water for injection.
Many facilities will run multiple processing suites simultaneously where some or
all of the above resources are shared between multiple processes. The advantage of
multiple suite operations is that the slot length can be increased with multiple batches
being processed simultaneously. The disadvantage is the difficulty in predicting how
the resource demands from one processing suite will affect the resource availability in
another.
To increase complexity further it is also important to consider the inherent uncer-
tainties present when processing biological materials. Cell culture product titre, process
yields, filtration flow rates, chromatography binding capacities and elution volumes are
just a few of the parameters which can see significant batch-to-batch variation. This
variation can lead to some batches falling outside the operating limits of a facility and
may result in product loss or the loss of entire batches. An understanding of the effects
of this variation can aid in the design of more robust processes.
Process design must be carried out with a view to the changing landscape of bio-
manufacturing. Predictions are that cell culture product titres will continue to increase
for both new products and throughout product life-cycles. This puts increased pressure
on purification which currently suffers from equipment size limitations for chromatog-
raphy columns, space constraints within facilities and time constraints to maintain the
production schedule. The option presented to developers is to either intensify existing
processes to remove bottlenecks or to investigate alternative technologies with fewer
limitations and greater scalability.
Process design should also be carried out whilst considering the entire lifecycle
of a drug product. This includes an understanding of the technology transfer activities
which will be carried at each phase from pilot to clinical and finally commercial scale
manufacture. This is not only a consideration of how processes will scale, but how
they will fit into the facilities into which they may eventually be transferred. These
facility fit assessments carried out early in the development of a process can highlight
potential sub-optimality in later phase processing and probabilities of product loss or
batch failure.
The need is for more systematic methods to capture the complexities of operating
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multi-product facilities, assess the impact of increasing titres at the process-business
interface and carry out facility fit assessments and root cause analysis.
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Chapter 2
Development of the Simulation
Framework
2.1 Introduction
This chapter outlines the development of the simulation framework from the definition
of the scope to a detailed description of the components within the framework.
2.2 Scope
The scope was defined as follows:
• To model multi-suite, multi-product facilities with different process sequences,
demands and performances for each product.
• To evaluate the performance of multi-product facilities across a range of cell
culture titres and scales based on cost of goods (COG), throughput, resource
utilisation and risk metrics.
The types of scenarios that the tool should be able to address were defined as:
• Operational Level
– Identification of facility limits at higher titres and testing of process inten-
sification strategies.
• Tactical level
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– Selection of optimum purification capacity to meet a schedule.
– Assessment of robustness of purification capacity to titre fluctuations.
• Strategic Level
– Prediction of failures upon technology transfer to larger facilities and root
cause analysis.
– Impact of developing alternative purification platforms.
2.3 Requirements Specification and Software Selection
Considering the tool scope and research focus a requirements specification for the inte-
grated software platforms was defined. The requirements specification for this frame-
work was adapted from previous work. (Farid et al., 2007) New key drivers for this
research included the need to share and manipulate large amounts of data as well as
to rapidly reconfigure multiple processes in a multi-product and multi-suite facility
whilst maintaining the ability to assess the impact of uncertainty and present the results
through novel visualisation techniques. The specification is outlined in Table 2.1.
Table 2.1: Requirements specification.
Requirement Type Specification
Representation of declarative knowledge Tasks and their characteristics
Resources and their characteristics
Material flow and its characteristics
Sequence of tasks
Resource requirements for each task
Calculation procedures for mass bal-
ances and costing
Variables for the calculation proce-
dures
Time
Hierarchical views of tasks
Continued on next page...
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Requirement Type (continued) Specification (continued)
Risk/uncertainty: stochastic variables
defined using probability distributions
Multi-product facilities
Facility definition
Processing Suites
Demands / Customer orders
Dynamic simulation Dynamic simulation of sequences
Dynamic allocation of resources to
tasks
Dynamic invocation of calculation pro-
cedure to compute compositions and
costs
Dynamic invocation of procedures to
compute resource utilisation statistics
Monte Carlo simulation
Single-threaded, multi-threaded and
parallel processing
Flexible development environment Graphical user interface
Modular
Extensible
Ability to store large amounts of data
Database driven
A key aim in the development of the software tool was the creation of a flexible
environment enabling users to specify a wide array of process sequences whilst having
minimal programming experience, to this end, it was seen as critical to maintain inde-
pendence between the data and the simulations. Input and output data accessed via a
database rather than being embedded in a programming language can provide the user
with a familiar environment similar to a spreadsheet or other data entry methods which
may be in use in legacy systems. As a result linking a database platform to a discrete-
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event simulation was found to be an efficient way of capturing all the requirements.
Multiple process simulations demand more complex data management compo-
nents than those available in the spreadsheet based simulation frameworks. To address
these issues, the MySQL distribution (MySQL AG. Uppsala, Sweden) of structured
query language (SQL) was chosen for implementation into this framework.
SQL is a powerful and flexible data storage engine, capable of handling the volume
of data and maintaining a logical structure for organising and relating information. This
ability to specify strict data structures in the form of related data tables and data type
definitions in addition to the large storage potential provides the framework with a clear
advantage over spreadsheet based approaches. Validation functions act to maintain the
integrity of the dataset by verifying the format of entered values as well as maintaining
referential integrity between the tables during update and deletion of data. Key database
fields are continually indexed to improve sorting and data retrieval operations to reduce
the simulation run times when operating with a large dataset.
Maintaining the database on a dedicated server allows for a more efficient work-
flow where analysis of data and the planning of future simulations can be carried out
while simulation jobs are in progress. Multiple networked computers connected to the
server provide the hardware framework to parallelise the simulation engines in the form
of a distributed cluster. This is advantageous when performing Monte Carlo simulations
where run times may be higher.
Extend (Imagine That! Inc, San Jose, USA) was selected as the discrete-event sim-
ulation package to simulate a wide array of processes with dynamic resource allocation
and scheduling. Discrete-event simulation models are composed of a series of inter-
connected blocks between which items containing variables or attributes move. The
blocks contain functions which generate simulation events. Events may act to delay
the progress of the item through the model such that subsequent events are generated
at a later simulation time. This functionality can be used when simulating any activity
which takes time. This is valuable when calculating the impact of resource delays (e.g.
due to labour constraints) and shift patterns on batch throughput.
SQL data access functionality is not available natively in Extend, rather the func-
tionality was developed using the proprietary compiled modelling language ModL,
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unique to Extend, and the Simulation Dynamics Industry Developer Application Pro-
gramming Interface SDIDAPI, a third party API. (Simulation Dynamics Inc. San Jose,
USA). This functionality uses Microsoft Open Database Connectivity (ODBC) as mid-
dleware to control communication between SQL and Extend. ODBC functionality was
further utilised to connect third party applications such as Microsoft Access and Sigma
Plot, for data entry, retrieval and visualisation. These connections are summarised in
Figure 2.1.
Database
MySQL
Data Connector
ODBC + SDIDAPI
Simulation Engine
Extend
Visualisation Tools
SigmaPlot
Data Connector
ODBC
GUI
MS Access
Figure 2.1: Diagram outlining the connection of third party tools to the simu-
lation framework. (ODBC = Open Database Connectivity, SDIDAPI = Simu-
lation Dynamics Industry Developer Application Programming Interface, MS =
Microsoft.)
2.4 Tool Implementation
2.4.1 Hierarchical Representation of Facility and Process Details
The representation of the key features of the manufacturing process addressed by the
tool was based on the hierarchical data structure outlined by Farid and co-workers
(Farid 2002; Farid et al. 2007a), in which different levels of detail of the process and
facility are defined. Figure 2.2 shows the interpretation of this hierarchical structure
through the use of a unified modelling language (UML) class diagram, which represents
key elements of the process to be implemented in the database and in the simulation
engine.
The UML class diagram is very commonly used as a standard language to specify
the structure of databases in an object-oriented way. In this diagram the different types
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Figure 2.2: UML Class diagram of the simulation framework. Some functions
and attributes have been removed for clarity. Each block shows the class name
and a list of selected attributes and operations. The various classes have been
grouped into packages. The classes in each package have similar or strongly
related functionality.
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of objects (classes) and their relationships are described.
In Figure 2.2 each block represents a class with a name (e.g. UnitOperation), a
list of attributes (e.g. stepID, stepType) and a list of operations (e.g. massBalance).
In this diagram a generalisation relationship exists between the class UnitOperation
and the classes representing the different types of step (UF/DF, VirusFiltration, etc).
It represents a relationship of type “IS A” (e.g. UF/DF is a UnitOperation). Classes
with similar functions or themes are grouped into packages (e.g. the Facility package
includes the classes to define suites and equipment.)
We can also see aggregation relationships (unfilled diamond and a line), specifying
“part-whole” relationships (e.g. a Campaign has BatchRecipes a BatchRecipe has Uni-
tOperations, etc). The multiplicity of an association is represented by the numbers next
to the lines (e.g. one Suite has exactly one SuiteType while one SuiteType can have
one or more Suites associated with it.). These part-whole relationships establish the
hierarchical nature of the framework: campaigns are at the highest level and sub-tasks
at the lowest.
2.5 The Database
2.5.1 Database Structure
The relational structure of the database implemented in SQL derives directly from the
class structure outlined in Figure 2.2. Bennett et al. (2005) present a set of rules to
correctly map the classes to database tables. In many cases where there are simple
one-to-one or one-to-many relationships between classes, these classes can be directly
translated to tables where the attributes become the fields and the relationships are en-
forced using foreign keys. An example using this form of mapping would include the
Campaign and BatchRecipe classes with the one-to-many relationship between them.
In this case, the BatchRecipe table contains the campaignID field from the campaign
table as a foreign key. The result is a single record in the Campaign table linked to
multiple records in the BatchRecipe table. A more complex mapping example would
be those required for the Buffer, BufferComponent and BufferRecipe classes. The re-
lationship between the Buffer and BufferComponent is a many-to-many relationship
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defined by the association class BufferRecipe. In the database these classes become
three tables with the BufferRecipe table containing foreign keys from both the other
tables. In this case, the relationship is enforced via the intermediate table. This rela-
tionship can be viewed graphically in the screenshot shown in Figure 2.3.
Figure 2.3: Screenshot of the buffer definition user interface. (a) buffer fields,
(b) bufferRecipe fields, (c) bufferComponents fields.
The tables in the database can be grouped in a similar way as the packages, how-
ever, the relationships between the packages are only realised when the simulation
engine brings the elements together in a simulation job. For example, it is during the
simulation that a particular equipment unit is assigned to a unit operation.
The tables in the Process package contain the information relative to the descrip-
tion of the process, from the batch name and input titre, at the highest level, to the
buffers and labour requirements for each individual sub-task. The Facility package
tables contain information regarding the structure of the facility and include the avail-
ability of suites and equipment. The Simulation package tables are used to define the
conditions of the simulation and how the base case data stored in the database will be
modified for each simulation job.
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2.5.2 Process Definition
Figure 2.2 shows that the Process package contains, amongst others, the five classes
which make up the process hierarchy: Campaign, BatchRecipe, UnitOperation, Task
and SubTask. Figure 2.4 shows a screenshot of the process hierarchy tables from the
BatchRecipe to the SubTask when viewed from within a Microsoft Access (Microsoft
Corp, Redmond, WA, USA) database connected to the SQL server. MS Access has
been used to demonstrate an example of a data entry interface where the user can drill
down through the hierarchy by expanding records to view the information in the level
below.
Figure 2.4: Screenshot of the process hierarchy data entry tables. This
screenshot was generated using Microsoft Access as the front-end to the SQL
database.
In Figure 2.4 a single batch record for Process A has been expanded to show the
unit operations. The first of these steps, affinity chromatography, has been further ex-
panded to expose the five tasks and finally the load/wash/elute task has been expanded
to view the six sub-tasks contained within. Values such as StepType and BufferID are
specified using drop down boxes, which contain values from other tables representing
different classes. For example, the BufferID field of the SubTask is the result of a re-
lationship with the Buffer class in the Facility package. Similarly the StepType field
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in the UnitOperation level is used to form the generalisation relationship, by selecting
the appropriate operation from the available types. This intuitive user interface struc-
ture is a direct consequence of the structure defined in SQL and serves to illustrate the
advantage of incorporating a relational database into the framework.
The definition of the process is done using scale independent parameters. For
example, in Figure 2.4 the buffer volume field on the sub-task is defined in a scale
independent parameter relative to the column volume of the step rather than in litres.
This is because the scale of the step, i.e the chromatography column volume, is not de-
fined until run time, using this notation ensure that the volume of buffer required scales
accordingly. Such scale independent parameters enable a single process to be used in
a range of investigations at different scales and with different facility configurations
without the need for modification within the database. This functionality is advanta-
geous when the framework is used to assess technology transfer challenges where a
largely fixed process will be simulated at a variety of scales from the pilot plant to full
scale manufacturing.
2.5.3 Facility Definition
The facility definition consists of several elements which define the infrastructure re-
sources such as the suites, vessels, and equipment as well as material resources such as
buffer components, filter membranes and chromatography resins. Data are also stored
that define labour availability and shift patterns.
In the database structure facility definition is defined independently of the process
description allowing the performance of a single process to be assessed in multiple
facilities. This is of particular use when considering process fit analyses for tech trans-
fer operations, where the aim is to assess the performance of a process in a variety of
facilities with differing capabilities.
Figure 2.3 shows the user interface for the definition of buffers. Buffers are stored
over three tables. Each buffer has one buffer recipe and it is composed of a number of
raw materials. By expanding each buffer the recipe for that buffer is displayed as a list
of part numbers and quantities. Clicking the drop-down box for each part provides a
list of available components. In the case of Figure 2.3, 15.1 g/L of NaCl is being added
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as a component of an elution buffer. The drop-down list is designed to show a useful
summary of the component list to the end user. The full buffer component table also
contains cost data which is used when calculating the total cost of the buffer during
simulations. This method of defining buffers by their components is a more efficient
method than specifying each buffer as an individual raw material. From the perspective
of data entry the costs of raw materials and recipes is more readily available information
than the costs of a buffer. It also allows for the easier investigation into the effects of
changing raw material costs since changing a single component cost will automatically
update related buffer costs.
2.5.4 Simulation Definition
Simulation jobs are defined using two tables in the database. The first of these provides
a unique identifier for the simulation job along with a description and the current status
of the job. It is this first table that the simulation engine interrogates to identify if there
are any jobs pending.
The second table records the specification of the simulation job. The rows in this
table are used to construct update queries which modify specific values in the process
and facility tables. The construction of the modifier queries will depend on the type of
parameters to be investigated.
The framework can be configured to run a number of simulation types. At the
conclusion of all simulations, the results are exported back to the database as a series
of archive tables. The results archive contains a copy of all input data tables as well as
dedicated results tables. A unique identifier field is added to each table to store the job
number such that the data from each simulation can be recalled at a later date
2.5.4.1 Base Case Analysis
The simplest simulation type, the base case analysis, uses data drawn directly from
the process and facility tables without modifiers. Simulations of this type are used to
provide a set of base case results to which other simulations can be compared. As
well as providing useful results, this type of simulation is used to validate the input
data. Errors in the input data which were not identified by the database will be reported
by the simulation engine. The speed of base case simulations makes them ideal for
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debugging operations.
2.5.4.2 Multiple Simulation Analysis
For more complex investigations multiple simulation jobs can be specified by using
modifier queries. This allows for the parameters in the base case to be changed auto-
matically without affecting the source data. The modifiers queries are stored in four
fields in the database which are combined by the simulation engine to generate a cor-
rectly formatted SQL query. This method can be used to define multiple jobs changing
a field value for each. During data analysis the jobs can be combined such that output
data can be linked directly to the changing input parameter.
2.5.4.3 Monte Carlo Simulation
The framework can also be used to run Monte Carlo simulations. Monte Carlo simula-
tions are defined using a similar method to the multiple simulation jobs with modifier
queries being used to define the parameters. There are however differences in how the
data in the process and facility specification tables is used and the way in which the
simulation engine runs.
In Monte Carlo simulation the sensitised parameters are stored using two fields
instead of the single field used in normal simulations. These two fields store the type
and bounds (e.g. type: triangular, bounds: minimum, maximum, mode). In Monte
Carlo simulations the simulation engine is configured to import the distribution data
instead of the single value field and generate a value within the bounds using a random
number generator.
The simulation engine runs a number of iterations in a single job using a different
random number seed for each. The number of iterations is specified in the simulation
tables. The simulation outputs a result set as with other simulations however in addition
to the unique job reference an additional field is used to store the run number. This
enables the results from runs to be analysed individually as well as together.
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2.6 The Simulation Engine
In order to maintain the flexibility of the framework, the model is required to be adapt-
able to a wide array of processes. To this end, a router-based simulation approach was
developed. Figure 2.5 shows how this approach was developed and how it differs from
traditional practices.
Centrifugation
Ultrafiltration
Chromatography
Virus Inactivation
Virus Filtration
Ultrafiltration
Chromatography
Chromatography
Ultrafiltration
Router
Virus FiltrationChromatography
UltrafiltrationVirus Inactivation
Centrifugation
(c)
(a) (b)
Router
EqO
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EqO
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Figure 2.5: Evolution of the simulation structure. (a) Linear, unit operation
based simulation approach. (b) Router and pre-defined unit operations. (c)
Router and generic equipment operations.
Figure 2.5a represents a more traditional approach, here a process is modelled as
a linear sequence of unit operations. Figure 2.5b shows how this linear structure can
be modified using a router. The limitation here is that it is difficult to model multiple
processes simultaneously as a single unit operation may be used in several processes.
The revised router structure shown in Figure 2.5c replaces the traditional unit operation
with a more flexible equipment operation. Each equipment operation contains the func-
tions to become any unit operation allowing the same type of operation to be carried
out in multiple nodes. In this approach all the nodes are identical and development is
simplified. This methodology is in-keeping with the software engineering principle of
abstraction which aims to reduce the amount of programming code through the use of
standardised functions and procedures.
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2.6.1 Class Implementation in Extend
ModL, the compiled language used in the Extend simulation, is similar to the more
common programming language C; as such there is no native object-oriented program-
ming functionality.
When creating the simulation functions, the SQL database tables or classes, are
associated with simulation blocks. Upon import into the simulation, the structure of
the tables is maintained however the relationships between the tables are lost. To main-
tain the integrity of the data after the import into Extend, an SQL function adds a coded
variable to the tables. The coded variable enables the correct object, represented by ta-
ble rows to be referenced by the simulation engine. The coded variable is an eight-digit
number assigned to each object in the BatchRecipe, UnitOperation, Task and Subtask
classes. The code is generated based on the position of the object within the process as
shown in Table 2.2.
Table 2.2: Construction of the coded variable.
Class Batch Unit Op Task Subtask Code
BatchRecipe 1 - - - 01000000
UnitOperation 1 2 - - 01020000
Task 1 2 3 - 01020400
Subtask 1 2 3 4 01020304
Functions in the simulation engine keep track of the current simulation position
such that the code can be generated at any point and used to retrieve the attributes for
the correct object. To access objects from other classes which do not contain the coded
variable, the code is first used to retrieve the primary key from one of the above classes,
this value is in turn used to identify the object attribute values in the related table using
the foreign key methodology discussed in 2.5.1.
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2.6.1.1 The Core Structure
The core of the simulation engine contains the primary elements such as the router
and the blocks responsible for simulating the unit operations as shown in Figure 2.6.
Elements outside the core contain functionality to simulate ancillary buffer preparation
and vessel cleaning.
2.6.1.2 Setup and Initialisation
The simulation begins with an initial setup and initialisation phase and includes the
functions of the SimulationJob and SimulationRun classes. These functions generate
the dataset for the current instance of the simulation by creating a temporary snapshot
of the database, modifying field values using the attributes defined in the Simulation
classes and transferring the dataset to storage local to the simulation instance. To avoid
conflicts between multiple instances of the simulation engine, the database is locked to
a single instance until the complete dataset has been defined.
Initialisation involves defining the simulation elements that will correspond to the
buffers, equipment and vessels, in essence configuring the model to represent the facil-
ity specified in the database. Using data regarding upstream processing (USP) opera-
tions, the frequency of batches entering DSP can be calculated and is used to generate
simulation items. Data are stored on items as attributes allowing for the passing of vari-
ables between the blocks in the simulation. An attribute on the item is initialised with
an increasing batch number used in the generation of the batch level coded variables;
this value will remain constant for the life of the item. Additional attributes for calcu-
lation of the unit operation, task and subtask coded variables are initialised to 1; unlike
the batch level variable these attributes will be incremented as the process progresses
through the simulation.
The items are independent and can take different paths through the simulation
engine blocks. The path taken by the items is defined jointly by data stored in the
database along with on-the-fly decisions made by the simulation. These decisions may
be affected by resource, facility and equipment constraints. It is this decision-making
ability that enables the simulation engine to simulate a wide array of processes without
modification.
2.6. The Simulation Engine 52
Data Import
Initialise
Simulation
Harvest
Vessel Allocation
Pre-calculation
and Optimisation
Suite
Allocation
Vessel
Allocation
Equipment
Allocation
Hold
Hold
Hold
Equip.
Op.
Equip.
Op.
Equip.
Op.
Equip.
Op.
...
...
...
U
n
it
O
p
e
ra
ti
o
n
s
R
o
u
te
r
In
it
ia
li
s
a
ti
o
n
&
S
e
tu
p
Figure 2.6: Core elements of the simulation engine. This structure enables the
route taken by the simulation items to be defined in the database rather than
as a fixed sequence of operations. The equipment allocation block carries out
mass balance calculations, identifies appropriate equipment and routes the item
to the corresponding equipment block. The structure of the equipment operation
blocks is shown in Figure 2.7.
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The process simulation now begins with vessel allocation. Depending on the pro-
cess specification the vessel allocated may be stainless steel or a disposable bag. Input
times to vessels are recorded in the database and will be used to calculate hold times
and vessel utilisation. Management of vessels will be discussed in a later section.
Each item passes through a pre-calculation and optimisation block. Using data
from the database the pre-calculation block performs a rapid analysis of the batch to
be simulated. The aim of the block is to arrive at the optimum process configuration
by identifying the equipment sizes able to process the batch within a desired deadline
whilst minimising costs. The pre-calculation block uses brute force optimisation, a
decision space of all the equipment size configurations possible is generated and the
configuration with the lowest cost and with a process time closest to the manufacturing
slot length is selected.
The optimisation routines are initialised by the OptimiseSchedule procedure as-
sociated with the Campaign class. This procedure serves a similar function the router
element of the simulation engine however instead of routing simulation items; the pro-
cedure calls the functions of the simulation engine to estimate the mass balance, buffer
costs and task times in the UnitOperation and Subtask classes. These functions are
being called programmatically rather than being triggered by simulation events and
therefore calculate parameters using an incomplete dataset. For example for the pur-
poses of estimation, all resources and equipment are considered to be unconstrained
since the data on resources usage is not available without running the simulation. The
result is an estimation of batch cost and time. The process time estimate is improved by
an additional procedure which attempts to account for process delays incurred through
shift based operation.
Once the cost and time for all the process configurations is complete, a procedure
selects the configuration that meets the processing time constraint at the lowest cost.
2.6.1.3 The Router
After the pre-calculation the items move into a series of blocks that determine the cor-
rect processing suite and allocate specific items of equipment and further processing
vessels. The selection of suites, equipment and vessels is done based on information
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stored in the database combined with data on the current status of the facility, i.e. suites
and vessels may already be in use and equipment may be utilised elsewhere in the fa-
cility. The functionality developed in the router element of the simulation engine is
key to the frameworks ability to adapt to any process and facility configuration speci-
fied. Establishing a clear set of rules enables the simulation engine to make decisions
which would otherwise have to be specified in the input data. This is time consuming as
any process or scale change could potentially require the user to manually specify new
equipment for each step. By taking an automated approach the performance of a fixed
process can be assessed rapidly across a range of facility configurations and scales.
In order to provide enough information for suite allocation, the suites in the facility
must first be classed by capability. For example a number of suites could be allocated
specifically for chromatography operations because they contain large tanks and chro-
matography rigs. In the process specification each unit operation is assigned to a suite
class. If classifying suites is not appropriate, the user can specify a range of suites in
which the step can be performed. This is less advantageous since these values must be
changed for each facility. The specific suite will be decided by the model at run-time
based on class and availability. If no suites are available, the batch will be routed to a
holding area and will be released when a suite becomes available.
After suite assignment, process vessels are allocated. With stainless steel vessels
the selection of the correct vessel may be dependent of the item of equipment selected
as well as the location of the suite. These limitations can be defined in the database;
the vessel allocation block identifies the correct vessel and allocates it to the batch. If
a vessel is not currently available the item will be routed to a holding routine until the
vessel is released. Allocation of vessels is based on location, availability and required
volume. It may also be based on a physical connection to a specific item of equipment
as may be the case for filtration retentate vessels.
For equipment allocation the simulation engine will select equipment based on
type, availability and a scale parameter. The scale parameter is a volumetric flow rate
range for chromatography and ultrafiltration rigs and a maximum process volume for
virus filtration. The scale parameter used for the selection of equipment was calcu-
lated by the pre-calculation block during the initialisation phase of the simulation. The
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equipment allocation block contains further balance calculations for the product across
the unit operation. The values generated here are more accurate than those estimated
in the pre-calculation since they represent the current state of the process including any
losses which may have been incurred previously. This more up to date information is
used to determine the correct filter areas and chromatography cycles. These functions
form part of the massBalance operation in the unitOperation class and use data from
specific unit operation type classes i.e. UFDF, VirusFiltration etc... The specific mass
balance calculations used will depend on the unit operation type of the current instance
of the unitOperation class.
Where multiple units of equipment are available the model will preferentially al-
locate any equipment which already resides in the current operating suite. This is an
important rule if we consider a process with multiple chromatography steps being car-
ried out in the same suite. If possible the same rig will be used for all operations thus
avoiding changeover delays.
Each item of equipment is assigned to an equipment operation block during ini-
tialisation of the model. The allocation of equipment directly affects the route taken
by the item through the simulation. This functionality is key the frameworks ability to
adapt automatically to the process and facility specified.
2.6.1.4 Unit Operations
The term equipment operation is used in the framework to describe those elements of
the simulation engine which contain functions to mimic the unit operations.
The equipment operation blocks contain the functions which allocate resources,
calculate processing times and handle the scheduling of sub-tasks. Once calculation in
these blocks is complete, the items are sent back to the router to be redirected to the
next operation.
Figure 2.7 shows a more detailed overview of the equipment operation blocks. The
path taken by the simulation items is shown as well as the lines of communications with
various resource manager blocks. The triggering of functions within the equipment
operation is iterative, with items cycling through the various elements within the sub-
task loop shown in Figure 2.7.
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Figure 2.7: Structure of the equipment operation blocks showing the sequence
of key functional elements used to simulate the unit operations and sub-tasks.
Each block corresponds to a section of programming code in the simulation.
The diagram shows the flow simulation items and therefore the order of execu-
tion as solid lines. Dashed lines indicate the communication necessary between
various blocks of the simulation engine. For example, when the buffer alloca-
tion block is triggered by the item, procedures in the buffer manager must be
triggered to determine the composition of the buffer and in turn the buffer must
be allocated to a vessel. This must be completed before the item moves on to
the process delay block which then determines the time taken to complete the
subtask.
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The number of iterations is determined by the sequence of sub-tasks and in the
case of chromatography the number of processing cycles.
Initialisation Upon entering the equipment operation blocks the current status of the
equipment is retrieved from the database to ensure that the item has not been sent to
a piece of equipment that is already in use or which has not yet been cleaned. If the
check fails the item is sent back to the router to be re-allocated otherwise the item can
continue to initialisation of the unit operation.
Initialisation involves retrieving the parameters from the internal database that
have been calculated by blocks earlier in the model. These items will be stored ei-
ther on the items as attributes or stored in local variables in the blocks for faster access.
A process vessel is also assigned at this point.
The item now enters into the sub-task loop. Control of this loop is handled by the
unit operation router. This block generates a number of simulation items depending
on the number of sub-tasks and cycles required. Items are generated to represent the
product as well as the pre and post product operations. This means that the item rep-
resenting the product is able to leave the unit operation and move on to the next whilst
other items continue any operations that are carried out after the product has left, such
as cleaning and dismantling the equipment. When multiple cycles of chromatography
are required the situation is more complex as an item is generated for each cycle of
product. This allows the cycles to continue processing independently if this is required
by the process. The allocation of items is shown in Figure 2.8.
On completion of the sub-task the process items are sent back to the router to be
either recycled through to the next sub-task or to trigger release of the product item.
At the end of processing the product item waits in the router to be released from the
unit operation and to be filled into the appropriate vessel. This release may also trigger
the next step in the process if desired. The release is triggered by specifically named
sub-tasks. In the case shown in Figure 2.8 the product item, which also represents the
load sub-task, will be released when the elute sub-task is complete and that item passes
through the sub-task router.
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Figure 2.8: The number and allocation of simulation items to sub-tasks for a
four cycle bind and elute chromatography step.
Sub-tasks The lowest level in the hierarchy of the process specification is the sub-
task level. Each unit operation is composed of a number of sub-tasks which take into
account the various operations which must be carried out in order to run the step. In
order to be classed as a sub-task the operation must require a process material, labour
or processing time. Process materials include WFI, buffers or the product. Examples
of sub-tasks can be seen in the data entry screenshot in Figure 2.4.
Processing time is calculated for tasks requiring process materials and is based on
volumetric flow rates which are defined in the process specification. If no buffers are
used, the task time must be recorded in the process specification.
In addition to being defined individually, the sub-tasks are also grouped. Grouping
is used to ensure that sub-tasks are carried out without delay. For example all tasks
between the loading and elution of a chromatography column will be contained in a
single group as it would be undesirable to hold the process at any point whilst product
is bound.
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Rules relating to the management of groups are maintained by the shift manager
element using data on the start and end time of shifts defined in the facility specification.
The functions here can result in three outcomes:
1. There is sufficient time left in the shift and processing of the group can continue.
2. There is insufficient time in the shift and the process is held until the beginning
of the next shift.
3. There is insufficient time in the shift however the process can continue in over-
time.
The third condition will only be met if an overtime allowance has been specified
in the facility specification. This condition will result in an increase in labour costs.
The shift manager uses data generated by the pre-calculation block as a more accurate
task time is not known until the sub-task time is calculated in the next block.
If the process is allowed to continue a more accurate sub-task time is calculated
and the resources are allocated.
Resource Allocation The resources to be allocated at the sub-task level are process
materials and labour. All process materials requests are handled by a resource man-
ager. The resource manager receives resource requests from the sub-task elements and
attempts to fulfil them without incurring process delays. In order to fulfil requests
the resource manager triggers buffer preparation operations, which include requesting
storage vessels from the vessel manager.
Buffer preparation tasks are independent of the main process sequence; however
they directly impact shared resources. Data regarding the buffer storage and buffer
preparation tanks is stored in the facility specification. These values will affect the rate
at which the buffers can be prepared as well as the number and volume which may be
stored at any one time. The buffer manager will trigger buffer generation if supplies are
low. The buffer preparation operations can be defined such that they do not constrain
the process. Here all demands for buffer are met without delay. In this case the requests
and profiles of buffer usage become a key output from the simulation.
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Labour allocation is controlled by the labour manager. As well as requests to
allocate labour to a task, the manager also receives notices that labour has been freed
up at the end of an operation. If labour is not immediately available a delay may be
incurred. In the sub-task, labour is allocated before the process delay and then released
after. The process delay is the point at which the time taken to perform the operation is
simulated. This is the time which is calculated by the process time block earlier in the
sub-task.
2.7 Data Visualisation and Analysis
Basic data analysis tasks can be carried out using SQL queries. SQL queries are par-
ticularly useful for pulling together related information from different tables in the
database and carrying out a calculation. An example of an SQL query is shown below.
2.7.1 SQL Query Example
The SQL queries and results are presented as viewed from the MySQL command line
tool. This example uses two simplified tables with sample data. An SQL SELECT
query is used to view the contents of the table. This query along with the output table
is shown in Figure 2.9.
mysql> SELECT * FROM subTasks;
+-----------+-------------+----------+-----------+
| subTaskID | SubTaskDesc | bufferID | bufferVol |
+-----------+-------------+----------+-----------+
| 1 | Equilibrate | 1 | 70 |
| 2 | Load | NULL | NULL |
| 3 | Wash | 2 | 100 |
| 4 | Elute | 3 | 60 |
| 5 | Equilibrate | 1 | 70 |
+-----------+-------------+----------+-----------+
Figure 2.9: SQL query and output table showing a list of subtasks.
A second query retrieves a second table outlining the buffers in use and is shown
in Figure 2.10.
The data in the two tables is of more use when the information is combined to
calculate the buffer costs. This is done be using a SELECT query which joins the data
and can calculate a new costs field as shown in Figure 2.11
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mysql> select * from buffers;
+----------+----------------------+----------+
| bufferID | bufferName | costPerL |
+----------+----------------------+----------+
| 1 | Equilibration Buffer | 0.5 |
| 2 | Wash Buffer | 0.7 |
| 3 | Elution Buffer | 0.9 |
+----------+----------------------+----------+
Figure 2.10: An SQL query to retrieve a list of buffers.
mysql> SELECT subTaskID, subTaskDesc, bufferName, bufferVol, costPerL,
-> (bufferVol * costPerL) AS bufferCost
-> FROM subTasks LEFT JOIN buffers USING (bufferID);
+-----------+-------------+----------------------+-----------+----------+------------+
| subTaskID | subTaskDesc | bufferName | bufferVol | costPerL | bufferCost |
+-----------+-------------+----------------------+-----------+----------+------------+
| 1 | Equilibrate | Equilibration Buffer | 70 | 0.5 | 35 |
| 2 | Load | NULL | NULL | NULL | NULL |
| 3 | Wash | Wash Buffer | 100 | 0.7 | 70 |
| 4 | Elute | Elution Buffer | 60 | 0.9 | 54 |
| 5 | Equilibrate | Equilibration Buffer | 70 | 0.5 | 35 |
+-----------+-------------+----------------------+-----------+----------+------------+
Figure 2.11: An SQL query to combine the data from two table to calculate the
buffer costs for set of subtasks.
The above query also carries out a simple calculation to determine the buffer cost
per step. A simple query can also be used to determine the buffer cost for all the
subtasks. This query is called an aggregation query and is shown in Figure 2.12.
mysql> SELECT SUM(buffervol*costperL) as bufferCost
-> FROM subtasks
-> LEFT JOIN buffers USING (bufferID);
+------------+
| bufferCost |
+------------+
| 194 |
+------------+
Figure 2.12: An SQL calculation query to retrieve the total buffer cost for a
batch.
This example is given using simplified sample data however the methods outlined
can be used to carry out the same simple calculations on even the most complex data
sets. The queries can be stored as functions such that a single word command can be
used to retrieve the required information.
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2.7.2 Third Party Applications
Any application with ODBC functionality can use the MySQL database as a data
source. This includes Microsoft Access (Microsoft Corp.) which provides a user-
friendly interface for generating complex queries and the ability to build intuitive user
interfaces using familiar windows forms. Data retrieved through Access can be copied
into other applications, such as Microsoft Excel where more complex analysis can be
carried out. This wide ranging third party application compatibility means the frame-
work will in many cases be able to integrate with legacy systems and work practices.
For convenient graphical analysis of the data, the SQL server can be linked to
SigmaPlot (Systat Software Inc. San Jose, USA). SQL statements can be stored in the
form of SigmaPlot Query Files which can be recalled to provide data for Sigma Plot
graphs. Since this method relies on stored queries, the same graphs can be reproduced
for different datasets without the need to rewrite the query. The enables the develop-
ment of a standardised reporting practices to provide consistent visuals and statistics to
decision makers.
2.8 Using the Tool
This section includes a selection of scenarios which are used to highlight the function-
ality of the simulation framework. The overall structure of the framework along with
the key input and output parameters is shown in Figure 2.13.
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eg. Description of suites
eg. Resource availability
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eg. Mass throughput
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Scale optimisation:
eg. Optimal equipment sizes
eg. Process robustness
OUTPUTS
Figure 2.13: Structure of the framework.
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2.8.1 Beginning an Investigation
The user configures the framework for their simulations by first defining a process and
facility definition in the database. In the prototype tool a user interface developed in
Microsoft Access helps to maintain the integrity of the data and provides the user with
a logical view of the whole process, a screenshot is shown in Figure 2.4. The database
validates all data entry and provides the user with feedback if invalid parameters have
been entered or if required parameters are missing. An overview of key parameters
required in the process specification is shown in Table 2.3.
Table 2.3: A list of key input and output variables to and from the
framework.
Inputs Outputs
Batch Parameters
Cell culture volume (L) Final output volume (L)
Cell culture product titre (g/L) Final product mass (g)
Unit operations general parameters
Sequence of tasks Buffer volume used (L)
Buffer type Calculated duration (hr)
Buffer volume per step (CV or
L/m2)
Task duration (optional) (2)
Labour requirement (FTE)
Step yields (%)
Chromatography
Bed height (m) Column diameter (m)
Linear flow rate (m/hr) Product load per cycle (g)
Packing flow rate (m/hr) Resin utilisation (%)
Dynamic binding capacity (g/L)
Product elution volume (CV)
Filtration
Diafiltration concentration (g/L) Filter Area (m2)
Over concentration (g/L)
Continued on next page...
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Inputs (continued) Ouputs (continued)
Cross flow rate (L/m2/hr)
Performance data (3)
Virus Inactivation
Acid titration (% of feed vol) Acid volume (L)
Base titration (% of feed vol) Base volume (L)
Inactivation hold time (hr)
Virus Filtration
Vmax (L/m2) Filter area (m2)
Average flux (L/m2/hr) Flush buffer used (L)
Max processing time (hr)
Flush buffer requirement (L/m2)
Once data entry is complete, a single base case simulation should be defined. On
either the same computer or a separate networked client the simulation engine should be
activated. The simulation engine will carry out further checks on the data and provide
further feedback to the user if errors are present. Correcting the data is iterative and
the base case simulation should be re-run until a satisfactory set of results has been
obtained. At this point the facility and process specification can be saved as data files
offline from the database and can serve as a starting point for all future investigations.
Multiple processes can be defined in the same way and schedules of manufacturing
campaigns and batches can be defined.
Once a satisfactory base case has been defined, more complex simulation runs can
be attempted by defining modifier queries and sensitised parameters for Monte Carlo
analyses. To analyse results, the user can execute predefined database queries which
calculate standard parameters such as batch costs, processing times, resource utilisation
and facility throughput. The simulation engine also maintains a log of key events which
occur during the simulation as well as parameters that are associated with these events.
Analysis of this log is useful as a starting point for root cause analysis especially when
carrying out Monte Carlo simulations. Typical log entries will include vessel overages,
resource conflicts and any other events which may result in process delays or material
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loss. Combining the values of the sensitised variables to the presence of certain log
entries can help identify the probability that these events will occur and when.
2.9 Conclusions
A novel framework has been developed which allows users to bring together multiple
process specifications with multi-suite facility configurations to provide insight into the
operation of modern multi-process biopharmaceutical facilities. A purpose built rela-
tional database has been developed and linked directly to a flexible simulation engine
through the use of industry standard data transfer middleware. Both simulation inputs
and outputs are stored in the same data structure and made available for data analysis.
Data analysis and visualisation is achieved using similar middleware to establish a link
between a wide array of third party applications, including Sigma Plot, Excel and MS
Access, and the archive of simulation results. This wide ranging compatibility also ex-
tends to legacy systems where data could be harvested directly from additional sources
such as data historians.
Maintaining data independence allows the database to become a central repository
of process and facility information and can facilitate efficient collaboration between
members of a process development or technology transfer team either locally or across
the globe via an SQL compatible web interface.
The structure of the database allows for processes to be specified using scale in-
dependent parameters. For each simulation the process specifications are paired to a
facility specification in addition to initial starting parameters to define the volume and
product titre in the cell culture. The remaining unit operations are sized automati-
cally by the simulation engine using the equipment available in the selected facility.
Where multiple process configuration options are available, the simulation framework
automatically selects optimum equipment sizes to minimise cost and scheduling bot-
tlenecks where possible.
The simulation engine has been designed to allow for both stochastic and deter-
ministic analysis though the use of Monte Carlo simulation. Unlike many systems, the
resolution of the data is maintained during Monte Carlo simulations giving the user
access to a complete dataset from every simulation iteration. This provides the user
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with the ability to drill down into the data set to identify root causes to potentially un-
desirable outcomes. Some of the processing overheads of running the large number of
iterations can be alleviated by operating multiple simulation engines in parallel as part
of a distributed cluster.
The following chapters show example case studies which serve to demonstrate the
range of simulation options available and show how by the development of complex
SQL queries, a wide array of data analysis operations can be performed.
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Chapter 3
Assessing Process Robustness and
Long-Term Facility Fit Using The
Database-Driven Dynamic Simulation
Framework
3.1 Aim
This chapter demonstrates the use of the database-driven discrete-event simulation tool
described in Chapter 2 for assessing process robustness and future facility fit. The case
studies focus on the ability of purification suites in an existing (CMO) facility to cope
with increased loads as a result of upstream advances in cell culture titres. A platform
monoclonal antibody (mAb) purification process is defined for the analysis, as well as
the features of a multi-suite clinical scale manufacturing facility.
The first case study focuses on characterising the throughput, economics and ro-
bustness of optimal process configurations at typical current titres. The second case
study extends this analysis to assess the long term fit of the platform process given a
range of equipment sizes available to enable scale intensification efforts. This is inves-
tigated over a theoretical 10 year period that sees titres increase from a modest 1g/L
to a challenging 10g/L. These case studies harness the benefits of the database-driven
approach developed using MySQL (MySQL AG. Uppsala, Sweden) to capture and ma-
nipulate the large datasets generated from brute for optimisation over a range of titres.
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Novel approaches to visualising process robustness and long-term facility fit are pre-
sented.
3.2 Introduction
As the biopharmaceutical sector has matured, increased scrutiny has been placed on
improving production costs and capacity utilisation. (Farid et al., 2005b; Jagschies,
2008; Kamarck, 2006) Consequently continuous improvements in platform technolo-
gies are being sought so as to keep manufacturing off the critical path whilst minimising
regulatory burdens. (Kelley, 2007; Davies et al., 2009; Farid, 2009; Sommerfeld and
Strube, 2005) This has become even more critical for cell-culture derived products such
as mAbs which have seen significant increases in mammalian cell culture titres. This
has not been matched by similar improvements in purification capacity.(Aldington and
Bonnerjea, 2007; Arunakumari et al., 2009)
As a result conventional chromatography-based purification sequences employed
in mammalian cell culture processes pose key capacity challenges as cell culture titres
continue to increase. This has shifted the focus of biopharmaceutical process devel-
opment efforts to re-evaluate the feasibility of conventional purification steps. (Kelley,
2007; Low et al., 2007) Downstream capacity bottlenecks potentially arise with in-
creased titres since they result in greater mass loads on chromatography steps and can,
for example, prompt a decision between opting for additional cycles or investment in
larger columns which may breach either time or budgetary constraints respectively.
Process scale intensification efforts require the ability to rapidly identify facility limits
as well as the sequence of optimal equipment sizes that minimise process cost whilst
satisfying time constraints. A further challenge is finding process configurations that
are both optimal and robust in the face of inherent uncertainties such as titre fluctua-
tions. Capacity planning endeavours are further complicated by facility resource con-
straints not only in equipment sizes and material availabilities for the unit operations but
also for hold steps and ancillary operations including buffer preparation. Restrictions
on the number and type of available suites pose a further scheduling challenge. The
complexity is further exacerbated when dealing with multi-product facilities and scale-
up of processes from a pilot scale facility to commercial manufacture. This chapter
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presents the application of the decision-support tool described in Chapter 2 to address
these facility fit challenges and hence facilitate in the design of robust and cost-effective
manufacturing strategies. More specifically to address the question: how will existing
facilities perform with the increasing titres?
Previous work on chromatography sizing optimisation has tended to focus on a
single chromatography step, For example Joseph et al. (2006) developed a technique to
assess the impact of titre changes on unit operations. Joseph et al. use a mathematical
optimisation routine which aims to find the optimum size and linear flow rate of a
protein A chromatography column for the purification of a concentrated mAb stream.
In contrast, this work focuses on chromatography sizing optimisation for a sequence
of three chromatography steps, (Protein A, anion-exchange, cation-exchange) so as to
determine the optimal configuration of each step across a range of titres that minimises
the overall process rather than a single step cost, whilst satisfying time constraints.
With multiple chromatography steps in a process, each with different resin costs and
binding capacities, all the process steps must be considered together as one complex
optimisation challenge in order to arrive at an optimum configuration across the whole
process. The result should in effect be the over-sizing of cheaper resin steps to free up
process time to reduce the size of more expensive operations, thus capturing the key
trade-offs across the whole process. This chapter demonstrates the key elements of
the simulation framework which were specifically designed to overcome some of the
functional limitations seen in previous models.
Applications such as Excel (Microsoft Inc. WA, USA.) and Superpro Designer
(Intelligen Inc. NJ USA) are commonly used to carry out investigations into facility
throughput, utility sizing and capital cost estimations. As static models, these tools
are not designed to react to dynamic factors such as resource and utility constraints or
handle the large datasets generated by brute force optimisation to determine optimal
Pareto frontiers. These two latter features are critical to the case studies in this chapter.
Hence
The tool described in chapter 2 builds on previous discrete-event simulation tools
created at UCL (Farid et al., 2005b; Lim et al., 2005, 2006). It has been developed
to link simulation and optimisation in a dynamic environment, whilst overcoming the
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limitations of spreadsheet applications when working with large amounts of data by
linking the simulation engine to a relational database. In order to provide a more com-
plete analysis, tools must be able to account for parameters which are time-sensitive.
This is especially crucial when considering the case that two key parameters of interest
are process time and cost. With the simplified assumption that any amount of mAb can
be captured from any scale of process given sufficient time, capturing and investigating
the trade-offs requires an accurate calculation of both elements.
3.3 Method
A base case process description was developed for the use in the case studies in this
chapter. The list of unit operations and information regarding the construction are de-
scribed in section 3.3.1. Additional information on the process used can be found in
Appendix A. The requirement to rescale the process at each titre point also prompted
the development of the process optimisation element of the framework which is dis-
cussed in section 3.3.2. Further detail on the process optimisation element can be found
in chapter 2.
3.3.1 Process and Facility Description
The common structural and chemical properties of all mAbs has enabled many manu-
facturers to develop platform processes for their production. This approach is aimed at
reducing development times and cost. A number of variations of these platforms exist
usually containing two or three chromatography operations which may or may not be
separated by ultrafiltration and diafiltration steps and include at least two methods for
virus inactivation and removal.
A typical mAb platform manufacturing process, variants of which can be seen
throughout the bioprocessing industry, was developed for use in a series of case studies
and is summarised in Figure 3.1 along with key parameters regarding the design of the
facility.
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Figure 3.1: Base case process and facility. On the left the process sequence is
shown along with the estimated processing times. Note the process is split into
three sections with each section aligned to a class of suite. The centre of the
diagram shows the number and type of processing suites within the facility. The
circles represent the different suites with the arrows showing the route process
material can take. CC = cell culture, Cent = centrifugation, ProA = Protein A,
VI = virus inactivation, UFDF = Ultrafiltration/Diafiltration, AEX = anion ex-
change, CEX = cation exchange, VRF = virus retention filtration, DSP = down
stream processing, VS = virus secure. On the right additional key information
is shown.
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For simplicity the manufacturing schedule consists of the single process utilising
all suites in a year long campaign. All studies were based on a clinical scale manufac-
turing facility with 2 x 2000L fermenters operating in a staggered mode, with a new
batch entering each of the DSP suites every 5 days. In this study a total of 10 campaigns
were run with titres increasing by 1g/L each year from 1-10g/L. This was designed to
be analogous to the expected trend of increasing titres over the next decade.
Three key metrics investigated in this analysis are:
• Annual batch throughput (Batches/annum)
• Mass product per annum (Kg/annum)
• Cost of Goods in DSP (RMU/g)
Throughput can be represented in terms of mass of product produced or the num-
ber of batches passing through the facility. Batch throughput for a contract manu-
facturer is of key importance, especially in facilities designed for clinical supply. An
increased number of clients passing through the facility at this stage translates into
a greater potential for ongoing collaboration at larger scale by increasing the pool of
clients and thus mitigating the risk of non-continuation of contracts for products which
fail in clinical trials. Mass throughput is of a lesser concern in this instance however it
is of interest as it provides the context of scale when considering the third metric, cost
of goods.
The case studies were developed based on a process deemed to be a standard plat-
form for the production of mAbs. The case studies were designed to investigate DSP
and as such USP operations were not modelled explicitly, Their effect was implied in
terms of a frequency of batches being received into DSP and calculated using equation
3.1.
fB =
⌈
TCC
NR
⌉
(3.1)
Where: fB = frequency of batches entering DSP, TCC = cell culture batch time,
NR = number of reactors. In both the case studies discussed, the cell culture batch
time was set at 14 days and there were 3 reactors, which resulted in a batch frequency
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entering DSP of 5 days. In turn this value as well as the number of DSP suites NDSP
was used to calculate the DSP slot length TDSP as shown in equation 3.2. With 2 DSP
suites available the slot length in this case was 10 days.
TDSP = fBNDSP (3.2)
The slot length was used as the scheduling constraint for the process optimisation mod-
ule. The decision space for the process optimisation was limited by investigating al-
ternative chromatography column diameters only. Filter areas were sized to process
material in a specified time and as such could be calculated. The facility was defined to
have a number of column diameters available ranging from 0.10m - 0.63m.
Using the above simple equations it is possible to account for the effects of cell
culture operations as well as some aspect of the facility construction, in this case the
mismatch between the number of cell culture reactors and DSP suites. Figure 3.1 out-
lines the USP/DSP mismatch, the sequence of unit operations, the DSP suites and how
the process was separated into the available suites. The number and allocation of suites
in the DSP operations do not have to be implied in the same as USP as the model was
designed to account for these.
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3.3.1.1 Key Process Assumptions
In order to arrive at a suitable process certain assumptions were required. These as-
sumptions are detailed in Table 3.1 below and their rationale is discussed in more detail.
Further assumptions can be found in appendix A.
Table 3.1: Key Process Assumptions
Parameter Step Assumption
Resin Reuse Protein A 100 cycles
AEX 50 cycles
CEX 100 cycles
Resin DBC Protein A 25 g/L
AEX 50 g/L
CEX 15 g/L
Resin Bed Height Protein A 20 cm
AEX 25 cm
CEX 25 cm
Max Filtration Time VRF 6 h
The ability to reuse resins is an important factor when calculating process costs.
In many cases the high cost of affinity resins can be mitigated by the ability to reuse
resins for multiple batches. In the case studies investigated in this chapter, the resin
reuse limits indicated in Table 3.1 were assumed. This is valid as the case study also
assumed the manufacture of a single product in a year long campaign.
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3.3.1.2 Key Process Costs
In order to calculate the cost of goods, costs for key process items had to be assumed.
Approximate values were provided by industrial collaborators and through discussion
with vendors and are shown in Table 3.2.
Table 3.2: Key Process Costs
Item Cost
Chromatography Resins
Protein A £8000/L
Anion Exchange £800/L
Cation Exchange £400/L
Filters
30kDa UFDF Membrane £800/m2
Virus Reduction Filter £1700/m2
Disposable Bags
500L Bag £450
200L Bag £400
100L Bag £350
50L Bag £50
Other
Labour £30/h
Of particular note in Table 3.2 is the inclusion of disposable bag costs. The base
case process was not designed to maximise the potential for disposable technologies,
however it was assumed that bags would be used for the storage of buffers and inter-
mediate product. It can be seen later in this chapter that the cost of disposable bags can
represent a significant proportion of the cost of goods for a process.
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3.3.2 Process Optimisation
The process optimisation element of the framework was specifically developed for the
types of analyses covered in this chapter. In a real facility unit operations are scaled
appropriately relative to the mass of product and volume of the process. Since the
process performance was investigated over a range of titres a method was needed to
scale to unit operations accordingly.
A module of the simulation engine was developed to automate certain elements
of process scaling. When used to investigate long term scenarios, for example the ef-
fects of increasing cell culture titres over 10 years, it is reasonable to assume that the
DSP process will be scaled up to meet the demands placed. This is achieved by spec-
ifying the process using, where possible, scale-independent parameters, for example
defining chromatography buffer volumes in terms of column volumes and filter buffer
requirements relative to membrane areas.
Based on equipment availability and the rules of scale-up the simulation engine
was able to generate a decision space which included every potential process config-
uration which could be achieved using the available equipment. In a process with 3
column steps and 9 different column sizes this resulted in 729 process options. Given
the run time of the simulation engine it was not practical to simulate all 729 options
therefore a pre-calculation module was developed to perform rapid calculations on all
the configurations to provide estimations of cost and processing time.
The structure of the pre-calculation module was based on that of the simulation
engine however compressed into a single block of programming code rather than the
approximately 5000 blocks which make up the simulation engine proper. In order to
achieve the processing time savings the functions of the code were concerned only with
the calculation of processing time and cost. The structure of the pre-calculation module
is shown in Figure 3.2.
The code of the router procedure shown in Figure 3.2 generates the list of process
configurations based on the process sequence and availability of equipment as spec-
ified in the simulation engine’s database. The procedure then called the correct unit
operation procedure where basic mass balance calculations were performed. The unit
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Figure 3.2: Structure of the pre-calculation block. The overall structure is sim-
ilar to the simulation engine however functions are concerned only with the
calculation of processing time and cost. Each box represents a programming
procedure or group of related procedures which carry out the calculations re-
quired.
operation procedure called functions which calculate filter, resin and bag costs for the
step. In turn these costs were added to the global process cost. The bag costs at this
point were for the intermediate products. Buffer and process timing information can
only be calculated with information from the subtask level of the database therefore a
subtask procedure was called which iterates through the subtasks of the unit operation
and calculates the buffer requirements and task times. The buffer requirements were
passed to a buffer cost procedure which in addition to calculating the buffer cost also
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passed information to the bag cost procedure to calculate the cost of the bags required
for buffer storage. Task duration information was passed from the sub task procedure
to a set of procedures which increment a global clock. The time procedures also take
into account shift durations and account for tasks which must be carried out in groups.
This for example avoids the potential for a shift change to occur between the time the
product is loaded and the time it elutes from a column.
For each process configuration the module calculates the estimated cost and pro-
cessing time. A set rule is then used to select the configuration with the lowest cost
capable of meeting the manufacturing slot length. This rule allows the simulation to
select a single process configuration out of the range of options available.
Taking the brute force approach to this optimisation challenge produces satisfac-
tory results as generally the availability of equipment results in a limited number of
options, the decision space can be reduced by actively scaling operations to meet a
schedule. For example certain operations may be sized to ensure that they are com-
pleted within a time limit, i.e a shift. where this is the case the equipment selection for
this operation and subsequently the decision space will be limited even further.
3.3.3 Model Specification for Case Studies
The simulation engine was configured to execute 10 simulation runs each with increas-
ing titre values between 1 and 10g/L. All other process and facility configuration data
were constant for all simulation runs, as a result, the decision space generated by the
process optimisation module remained constant for all simulation runs. The output
from each simulation run consisted of a table of costs and times for each of the 729
process configurations investigated. Each process configuration was given a unique
identifier which was exported along with the cost and time data. In total 10 tables were
generated and analysed. To reduce the size of the dataset only processes configurations
which fall on the Pareto frontier of a cost versus time space were investigated.
Outputs from the simulation engine were exported to Excel where the Pareto fron-
tiers were automatically extracted using a procedure written in Visual Basic. The pro-
cedure identified the Pareto frontier by comparing the point, x(A,B) to all other points,
n(A,B) in the decision space and determining if there were any points which have lower
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values of both A and B. If the test was true for any n(A,B) then x(A,B) cannot fall on
the Pareto frontier. Each point in the decision space was tested using this rule allowing
all points on the Pareto frontier to be identified. Sigma plot was used to visualise the
Pareto frontiers for all simulation runs. The points on each Pareto frontier from the
same process configuration were joined to form a series of vertical tie lines to easily
identify those processes which appear on multiple frontiers. This is possible since the
process and facility configuration and hence, decision space remained constant between
each simulation run.
3.4 Results
The studies were designed to test the simulation engine and to provide insight into the
operation of multi-suite mAb manufacturing facilities and when and how the trend of
increasing cell culture titres may affect their design. The process and facility used for
the case studies is outlined in Figure 3.1.
The first case study looked at investigating the performance of a current manufac-
turing facility running an existing mAb process. The aim was to identify the limitations
of a typical manufacturing process with respect to increasing titre and where, within the
process, these limits are likely to be reached.
The second case study expands on the process optimisation elements of the sim-
ulation engine and demonstrates how using the limited information provided by the
optimisation module it is possible to arrive at conclusions regarding robust facility de-
sign in a future of increasing titres. Specifically, it focused on assessing the robustness
of optimal configurations to batch-to-batch titre variability as well as identification of
facility limits at high titres.
3.4.1 Case Study 1 - Throughput and Process Economic Analysis
The tool was initially used to characterise the throughput bottlenecks in an existing
facility originally designed so that the DSP capacity matched harvest loads from cell
cultures. However the facility had a range of available chromatography column diam-
eters (0.1-0.63m) for each of the steps in the fixed DSP sequence outlined in Figure
3.1. Hence conventional scale-up could be replaced with scale optimisation to max-
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imise throughput whilst minimising cost as titres increase. At each titre in the range
1-10g/L, the tool’s brute force optimisation module was used to identify the optimal set
of column and filter sizes that minimise the DSP batch materials costs whilst satisfying
the 10 day slot length for DSP so as to maintain the batch schedule. These optimal
configurations were then run in the discrete-event simulation engine to determine their
performance characteristics given possible resource constraints and time delays.
Figure 3.2(a) shows the facility throughput in terms of mass and number of batches
per annum across the titre range 1-10g/L at 2000L scale. This highlights the titre levels
at which the throughput bottleneck would occur in this facility after scale intensifi-
cation, as represented by the pointe where the batch throughput drops sharply and the
mass throughput levels off. In this case the bottlenecks occur above titres of 6g/L which
indicates that the DSP can handle harvest loads of up to 12kg/batch.
The theoretical maximum batch throughput is calculated using the following for-
mula:
NB =
ND
fB
(3.3)
Where: NB = Number of batches per year, ND = number of continuous operating days
per year, It was assumed that the number of operating days was 365 and cell culture time
was 14 days with 3 reactors; this results in a maximum theoretical batch throughput
of 73 batches per annum. The maximum batch throughput shown in Figure 3.2(a) was
slightly lower than the theoretical value as processing on the final 1 or 2 batches was not
always complete before the simulation end point. Data is only analysed for complete
batches.
The data generated by the simulation was examined to trace factors contributing to
the facility limits. The simulation aims to maintain a schedule and as such batch time
is strictly controlled through the adjustment of equipment sizing. Since the frequency
of batches entering DSP is fixed, for a bottleneck to be present the batch time must
have increased above the slot length. Figure 3.2(b) shows that this is the case, where
the batch time can be seen to increase dramatically at titres above 6g/L. At lower titres
the batch time value reaches the maximum slot length value and is evidence that the
optimisation routine is functioning correctly. Below 6g/L the number of cycles and
batch time fluctuates around the slot length as only discrete column sizes are available
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(a) (b)
(c)
Figure 3.3: Impact of titre on throughput-related parameters: (a) Annual mass
produced (◦) and batch throughput (H), (b) Average batch time (◦) and number
of chromatography cycles (•), (c) column diameters for protein A (•), anion
exchange (◦) and cation exchange (H). In (b) The average batch time is the
average duration of all completed batches within the year of operation. The
chromatography cycles is the sum of the number of cycles for all steps. The
horizontal line at 10 days shows the DSP slot length. In (c) the column diameters
were selected using logic built into the brute force optimisation module of the
simulation engine.
so the number of cycles required is not always directly proportional to titre.
Figure 3.2(b) shows that as titres increase the optimisation routine can no longer
locate equipment sizes to maintain the slot length and correlates the batch time to the
number of chromatography cycles. This relationship is evidence that chromatography
operations are the root cause of the DSP bottleneck in this process, with insufficient
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capacity to handle the larger product masses within the desired batch slot length.
The optimisation block has a contingency for when no processes meet the schedule
constraint, at this point the fastest process will be selected. This configuration will have
the largest columns and lowest number of cycles. At all titres above the bottleneck point
the maximum column diameters will be chosen leaving increasing cycles as the only
option to handle the increased load. To confirm this, Figure 3.2(c) shows the column
diameters selected for each of the chromatography steps. Beyond 6g/L all columns in
the process are at 0.63m in diameter since this is the maximum column size available
to the process and is the result of a physical facility limitation.
In order to de-bottleneck this process, solutions must either increase the available
processing time in the slot, improve other unit operations to make more time for chro-
matography or improve the chromatography steps to achieve the same separation in
less time or with smaller columns.
In addition to throughput, cost is also a significant factor when analysing process
performance. To investigate cost the model provides data for the COGDSP for future
titres as shown in Figure 3.4. COGDSP includes overheads, labour, raw materials and
consumables costs such as disposable bags, resins and filter membranes for all DSP op-
erations. COGDSP is seen to reduce significantly with titre, and up to 6g/L the benefits
of increasing titres is clear. Beyond 6g/L the results suggest a change in the relation-
ship between cost and titre and the values remain largely constant, beyond 6g/L there
is no cost advantage to increasing titres. Un-constraining the facility by introducing
larger columns does not have a significant impact on this value as the base case as-
sumes the reuse of resins over multiple batches, a reasonable assumption for a single
product facility. The increase in overhead operating costs which may be a consequence
of purchasing the larger columns is not taken into account here.
To formulate a plan for optimising the costing it is useful to look at the breakdown
of costs to identify areas of the process where changes will have the largest impact.
Figure 3.5 shows the percent breakdown of the main consumables costs for the optimal
process configurations in the processes and how the values change with titre. Most
notably all costs increase almost linearly with titre up to the bottleneck point of 6g/L,
beyond this point the relationship changes and the values remain approximately con-
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Figure 3.4: Cost of goods in down stream processing (COGDSP) vs. titre.
COGDSP includes facility overheads, labour, chromatography resin, filter mem-
branes, disposable bags and buffer components including Water for Injection
(WFI) (at 1.50 RMU/L) for all unit operations occurring post harvest.
stant.
The same costs this time as a percentage of total annual material costs are shown
in Figure 3.6.
The reducing proportion of resin costs can be attributed to more cycles in chro-
matography achieving better utilisation of resins. The larger resins and increased num-
ber of cycles is the largest contribution to the increased proportion of buffer costs.
Finally, the proportion of bag costs plateaus as the larger requirement for each buffer
translates into increased use of the larger bags; the bag cost per litre of buffer in a full
100L bag is 3 times greater than a full 500L.
Because of a general lack of information as to the true cost of WFI, Figure 3.6
shows the same data at two WFI costs. At either rate, the data points towards the
buffer costs being most significant at all but the lowest titres and highlight an area for
further investigation. A useful metric calculated by the simulation engine is the amount
of buffer required per gram of product. In this process and facility studied the value
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Figure 3.5: Actual annual material costs vs. titre for base case process. Costs
have been separated into disposable bags (), buffers (•), chromatography ma-
trices (◦) and filter membranes (). Buffer costs include WFI at 1.50 RMU/L.
was calculated at 5.2±0.3 L/g and was constant across the whole range of titres. This
presents another issue in that a 10 fold increase in titre and hence output, will result in
a 10 fold increase in required buffer capacity.
As titres increase the process volumes increase, this results in increased diafil-
tration needs leading to an increase in membrane area needed to process the material
at higher flow rates in an attempt maintain the schedule, it also accounts for some of
the increases in buffer costs as there is an increased need for diafiltration buffers. The
overall percentage cost of membranes however does not change with titre.
To start an optimisation study, it is useful to identify where in the process the
buffers are consumed. When buffer use per step is expressed as a percentage of buffer
consumption across the whole process the values remain constant across a range of
titres. The process data was extracted from the database and is summarised in Figure
3.7. The steps with the largest consumption in this case are protein A and anion ex-
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(a)
(b)
Figure 3.6: Impact of titre on percentage breakdown of material costs at 2 WFI
rates for base case process: (a) WFI cost = 1.50 RMU/L, (b) WFI cost 0.10
RMU/L. Costs have been separated into disposable bags (), buffers (•), chro-
matography matrices (◦) and filter membranes ().
change chromatography and can therefore be considered as targets for optimisation. In
this example the two steps utilise 78% of all process buffers.
This result is not surprising given their lower resin dynamic binding capacities
(Table 1) combined with the need for higher numbers of buffer CVs per cycle; for
example, the adoption of 27 CVs/cycle in Protein A versus 1820 CVs/cycle for ion-
exchange steps is largely due to the more complex wash steps that are often adopted in
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Figure 3.7: Buffer volume required per annum for selected unit operations. Per-
centages are shown for protein A chromatography (•), anion exchange chro-
matography (◦), cation exchange chromatography (H), virus reduction filtration
(4) and ultrafiltration/diafiltration (). The process contains three ultrafiltra-
tion diafiltration operations which are combined here into a single result set.
Total annual buffer consumption includes the buffer used for all unit operations.
Protein A so as to maximise yields.
The long terms effects have the potential to be significant and may lead to a situ-
ation where the buffer demands cannot be met at large scale. Potential solutions exist
and may include inline buffer dilution. Whilst reducing the size of buffer prep and
storage tanks, inline dilution requires a reliable, constant supply of water for injection
(WFI) and the potential exists for a shortfall in WFI generation rates to delay processes.
3.4.2 Case Study 2 - Process Robustness Under Uncertainty
The data generated by the process optimisation routines used to reconfigure the process
at different titres can itself be analysed to capture the robustness of process configura-
tions to titre variances. Using this approach the same information can be used to not
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only optimise the process selection for a single titre value, but can also be used to select
a configuration which is optimum over a range of values.
Figure 3.8 shows the decisions space for all the process configurations considered
by the model for a set titre of 2g/L. Each point represents the key objectives/perfor-
Figure 3.8: Batch cost vs. batch time for number of process configurations
considered by the model framework. In this case, the framework is attempting
to optimise the sizing of the columns for the 3 chromatography operations in the
process. Also shown is the Pareto frontier on which the optimum configuration
should lie and the ideal processing time is shown as a vertical line at 10 days.
The size of the point symbol is proportional to the affinity column diameter.
mance metrics to optimise, DSP batch material cost and batch time for each process
configuration. The Pareto frontier shows those configurations which are neither cost or
time dominant and is a method to reduce the process choices to those which are feasi-
ble. A vertical line also shows the maximum batch time (10 days) and is an additional
constraint. The optimisation routine aims to find the lowest cost process below the slot
length, represented in this case by point A. Arguments can be made for additional logic
which could arrive at different points. For example, point P may be desirable since
the process cost is higher however the process fits better into the schedule, minimising
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downtime. From a purely cost perspective point Q is more appealing. Figure 3.8 also
provides some additional information on the sizing of the affinity step where the size of
the point is proportional to the size of the column. The trend is for column sizes to de-
crease as processing time increases as indicated by the larger points size on the Pareto
frontier a the low processing times relative to the high processing time. Interestingly
the lowest cost process to operate contains the smallest affinity column step highlight-
ing that protein A is a key cost driver in mAb processes, backing up the finding from
the first case study.
Although valuable insights can be gained from analysing the options at a fixed
titre, the data does not provide an indication of the robustness of the optimal config-
uration to expected batch-to-batch variability. The analysis was therefore extended to
provide a novel method for visualising the robustness of process configurations to typ-
ical titre fluctuations. Similar decision spaces were generated at 1.5g/L and 2.5g/L to
represent ±0.5g/L titre fluctuations. To simplify the visualisation, only the Pareto op-
timal fronts were plotted (Figure 3.9). In figure 3.9 the points labelled A - C are the
same process configurations as labelled in 3.8.
The location of each configuration on each frontier was identified and connected
with a linear tie-line, since DSP batch materials cost and time were found to vary lin-
early with respect to titre. To be considered robust, the selected configuration should
now span the 1.5-2.5g/L range without exceeding the maximum slot length. Further
Pareto frontiers were generated with the titre fluctuation range with 100 titres selected
randomly from a triangular titre distribution, Tr(1.5,2,2.5) so as to determine the like-
lihood of a configuration exceeding the batch slot length. The enhanced dataset in
Figure 3.9 illustrates that although configuration A is optimal at 2g/L. as the titre in-
creases towards the upper fluctuation boundary of 2.5g/L it’s slot time exceeds the max
slot length. Configuration A was found to be feasible for only 80% of batches given the
expected titre fluctuations. Process r is more capable of handling the increase in titre;
however it ceases to be on the Pareto frontier at low titres, this suggests that although
this process would still be feasible at the lower titres there would be a more optimal so-
lution in this region. Configuration B would be an optimal solution for 96% of batches
at only an average increase in cost over configuration A of 1.3% and a processing time
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Table 3.3: Chromatography column configuration for processes selected in Fig-
ure 3.9. Change in costs and time are quoted relative to process A. Titre = 2g/L,
Harvest = 4kg/batch.
Column Diameter (m)
Process Affinity CEX AEX % Feasible ∆ Cost (%) ∆ Time (%)
A 0.30 0.30 0.45 79 0.00 0.00
r 0.30 0.35 0.45 69 +0.98 -1.51
B 0.30 0.30 0.63 96 +1.26 -4.31
s 0.35 0.30 0.45 71 +2.13 -4.53
C 0.45 0.30 0.45 100 +2.40 -9.07
reduced by 4.5%. In order to handle 100% of the processes within the expected titres
configuration C would be the most robust option. Configuration A would incur a 2.4%
increase in cost over A with a 9.1% reduction in processing time. Configurations r
and s shown in figure 3.9 are examples of processes which beyond certain titres have
drifted away from the Pareto front and are therefore not present on the Pareto front
across the whole titre span. As only those process on the front are shown, the tie lines
are curtailed.
Visualising the robustness of the configurations to titre fluctuations in this manor
allows identification of alternatives to Configuration A that may ultimately be better
selections. Decision-makers can then assess the level of desired robustness versus the
probability of either delays or discarding product to meed the slot length.
The method used above can be taken a step further to provide information to drive
future facility design. Figure 3.9(a) again shows the Pareto frontiers for a range of titres
to represent the 10 year titre trend of 1-10g/L.
Given an existing facility and specifications for a process this figure allows the user
to rapidly assess the limits in which the facility is able to operate and how sensitive the
material costs and batch time are to changing titre for each of the configurations shown.
In this case a 10% increase in titre will result in an increase in batch time of between
6.9-7.4% and an increase in cost of between 5.2-8.7% for a fixed process configuration
and scale. These values cover all optimal configurations within the facility and can be
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Figure 3.9: Horizontal curves are the Pareto frontiers of data generated after
simulating 100 processes. Each process has a differing titre varying randomly
within a triangular distribution. The triangular distribution had a minimum of
1.5g/L, a maximum of 2.5g/L and a mode of 2g/L. Identical process config-
urations on each Pareto frontier have been joined as shown by the red lines.
The gradient of these line show how a set process configuration is sensitive to
changes in titre with respect to batch cost and process time. Selected processes
have been labelled and Pareto frontiers for 1.5, 2 and 2.5g/L have been added for
clarity. A vertical line at a batch time of 10 days represents the ideal maximum
processing time.
useful for assessing the impact of changes in USP on DSP.
The figure also allows the user to assess the impact of imposing scheduling con-
straints. In this case an operating time of 10 days is shown by the vertical line. Now the
region of operation is reduced to the area to the left of the line. It is also possible to see
that the imposed schedule constraint does not allow the facility to reach the maximum
investigated titre of 10g/L. In this instance the maximum titre achievable is 6g/L. With
the additional simulation data available it is possible to identify the configuration able
to achieve the maximum titre and investigate further. As has already been established
in the previous case study this facility is limited by the maximum available chromatog-
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Figure 3.10: (a) Pareto frontiers for titres between 1-10g/L. As in Figure 3.9
straight lines show the changing cost and batch time of a process configuration.
(a) Data from (a) is overlaid against data obtained from an investigation into the
impact of having chromatography column with larger diameters available for
processing.
raphy column diameter due to space constraints. A further scenario investigated the
impact of making larger columns available. Figure 3.9(b) shows the impact of increas-
ing the maximum column diameter from 0.63m to 0.75m. The impact of adding the
new column is to increase the area of the operating region and raise the maximum titre
to 8.8 g/L (17.6kg harvest/batch). It also shows that if the slot length could be increased
by just a single day, a configuration is available to process a 10g/L batch. It is impor-
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tant to note that increasing the column diameter will not have this effect if there is no
packing or operating skid capable of handling the increased volumetric flow rates. In
this case the simulation engine assesses the availability of additional equipment when
considering process configurations.
Where the aim is to provide insight on facility design, instead of providing data on
equipment availability within a facility, information on commercially available equip-
ment can be used. With knowledge of the expected scale of operation, additional in-
formation on schedule constraints can be used to narrow the region further if need be.
The result will be a list of optimal configurations, that can be cross-referenced in the
simulation database to identify the equipment needed to meet to design a facility to
operate within the specified limits.
3.5 Conclusions
This chapter has outlined and demonstrated an approach for developing a flexible mod-
elling tool to aid in process development. The tool was used to investigate a standard
mAb manufacturing process at 2000L scale and has provided insight into the opera-
tion of such processes in an environment of increasing titres. The simulation engine
provided data to identify and investigate facility bottlenecks and assess the impact of
the bottlenecks on key performance parameters including costs and throughput. Novel
methods were developed to graphically represent the robustness of a large number of
process configurations on a single two dimensional plot. These methods were further
expanded to visualise the effect of expanding the capability of a facility and process to
improve long term robustness in an environment of increasing titres.
The widely held belief that affinity chromatography in its current state will be-
come the bottleneck of the process, has been supported. It is worthy of comment that
the bottleneck in many facilities is going be to felt well before columns reach the cur-
rent maximum of 2m. More likely, the facilities will reach a point at which they are
unable to store the volumes of buffer required for processing material. Alternative
buffer preparation methods, such as inline dilution, may compensate for shortfalls in
the installed tankage however, this places increased pressure on WFI generation, with
generator failures now far closer to the critical process path.
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Alternatively, purification processes that actively seek to reduce buffer demands
may be necessary such as the adoption of next generation resins with higher resin bind-
ing capacities or alternatives to packed-bed chromatography such as single-use mem-
brane chromatography. These process changes may be particularly relevant to facilities
that have been designed with higher ratios of USP to DSP trains, and hence shorter
DSP slot lengths, than presented in this study where scale intensification alone may not
be sufficient to cope with increasing titres.
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Chapter 4
Integration of Stochastic Simulation
with Multivariate Analysis: Short
Term Facility Fit Prediction
4.1 Aim
The previous chapter outlined a method to visualise long term facility fit and inves-
tigated the effects of increasing titre. This chapter describes a decision-support tool
that integrates Monte Carlo simulation data derived using a stochastic discrete-event
simulation model to mimic process fluctuations with advanced multivariate statistical
techniques to help pinpoint the potential root causes of sub-optimal short term facility
fit issues. Principal component analysis combined with clustering algorithms was used
to analyse the complex datasets from complete industrial batch processes for biophar-
maceuticals. The challenge of visualising the multidimensional nature of the dataset
was addressed using hierarchical and k-means clustering as well as parallel co-ordinate
plots to help identify process fingerprints and characteristics of clusters leading to sub-
optimal facility fit issues. Industrially-relevant case studies are presented that focus
on technology transfer challenges for therapeutic antibodies moving from early phase
to late phase clinical trials. The case study details how sub-optimal facility fit can be
alleviated by allocating alternative product pool tanks. The impact of this operational
change is then assessed by reviewing an updated process fingerprint.
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4.2 Introduction
Long term facility fit issues are generally concerned with the future proofing of man-
ufacturing facilities and platform processes (Chapter 3). Any challenges highlighted
can be addressed over time with the development of new technologies and large capi-
tal projects. Short-term facility fit issues are those that arise due to the batch-to-batch
variability associated with a single process. There may be insufficient time to make
significant changes to facilities so early identification of issues is crucial.
Technology transfer of pilot scale processes into facilities during late phase clinical
trials of a drug candidate can often lead to short term facility fit issues. Hence, it is
common practice in industry to perform a facility fit assessment during the initial stages
of tech transfer of a manufacturing process into a larger commercial scale facility.
This chapter builds on the flexible database-driven simulation platform described
in Chapters 2 and 3 that captures the mass balances, equipment sizing, dynamic re-
source allocation and process economics of purification sequences in monoclonal an-
tibody manufacturing processes. Chapter 3 discusses the use of the tool to perform
a small number of simulation runs to generate sufficient data to assess the impact of
a single parameter change. This chapter describes the extension of the tool to mimic
the stochastic nature of industrial batch processes when transferred to large-scale fa-
cilities and to identify the potential root causes of short term facility fit issues. This
was achieved by building in capabilities to run Monte Carlo simulations and exploring
how best to integrate stochastic results into advanced multivariate statistical analysis
techniques.
Monte Carlo simulations result in very large datasets and hence visualising the
results of the MVA becomes more challenging. Although PCA might reduce hundreds
of datasets to a few principal components, it does not automatically identify clusters
of batches with similar characteristics for further examination. Hence in this article,
algorithms adapted from Thornhill et al.(Thornhill NF, 2006) are used to achieve hier-
archical and k-means clustering of the datasets so as to identify significant clusters of
batches. Multidimensional visualisation of each clusters characteristics in terms of the
raw data (e.g. product titre in cell culture) is achieved through the generation of novel
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multiple stacked parallel co-ordinate plots; this is in contrast to other works (Wang
et al., 2004) where parallel co-ordinate plots are used to plot PC scores rather than re-
verting to the actual process data. The resulting facility fingerprints enhance process
understanding of interactions between variables in an informative and clear manner.
4.3 Problem Domain
Upon technology transfer of a process from pilot scale to large scale, a current good
manufacturing practice (cGMP) engineering batch is normally carried out to test per-
formance and identify facility fit issues. Until this point, data is only available from
the laboratory and pilot scales of the process. The first batch at large scale is sub-
ject to a much greater degree of uncertainty that would normally be expected between
subsequent batches. This uncertainty is due in part to scale effects such as variability
introduced by operating larger chromatography columns or increased product holdup
in systems. The impact of this variability becomes more exaggerated at large scale
where any equipment limitations are difficult to adapt to. As a result, the first batch at
large scale is more difficult to predict than any other batch. THree key parameters were
identified as key to the variability at scale: product titre, step yields and chromatogra-
phy elution volumes. These were derived through extensive discussions with industrial
practitioners involved in tech transfer as well as literature sources. Representative trian-
gular distributions were derived through these discussion with industrial experts (Table
4.1).
Whilst sensible ranges in process variability were sought for each of the parame-
ters, the primary aim of this chapter is to demonstrate the application of the proposed
methodology to perform more rigorous and predictive facility fit assessments by lever-
aging process fluctuation datasets to determine both the likelihood and root causes of
product loss. Hence, the actual inputs and answers should not be seen as definitive
but an illustration of how to approach such an assessment. Triangular distributions
were chosen due the limited availability of empirical data on which to base a more data
driven decision. These three sources of variability are discussed further below.
Product Titre. Variation in the total amount of product entering into the purification
process is felt across all chromatography steps since the number of cycles is determined
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by the mass load of product, making it an important parameter to capture. Batch-to-
batch variability as well as variability in titres across scales is commonly seen due to the
inherent uncertainty associated with biological systems. A value of ±10% was deter-
mined through discussions with industrial advisors and represents a conservative level
of batch-to-batch titre variability.(Legmann et al., 2009) However, a wider range of titre
fluctuations may need to be considered for some products, especially where the differ-
ences in scale upon tech transfer are large and where tech transfer occurs before the
detailed process characterisation scale-down studies. For example, published reports
show small-scale bioreactors predicting titre profiles within ±20% of the historical av-
erage of large scale runs.(Amanullah et al., 2010; Abu-Absi et al., 2010) Contributing
factors include: changes in vessel geometry and subsequent hydrodynamic affects, raw
material sourcing, the differing levels of control of critical factors such as pH, temper-
ature, inoculum transfer times, and gas mixtures within different reactors. The impact
of these factors is complex and results in varying levels of uncertainty for different
products and cell lines.
Step Yields. Variation in yield losses across steps are typically small as represented
by the relatively narrow ranges specified in Table 4.1. The case studies in this chapter
are concerned with a hypothetical first batch at scale where fine tuning with respect to
minimising yield losses such as optimising flush volumes to minimise losses through
holdup may not have been fully identified. Hence this variation may be reduced further
over subsequent batches.
Chromatography Elution Volumes. Variability in the eluate volumes from the chro-
matography operations was highlighted as a significant factor impacting facility fit at
scale during discussions with industry experts. When using collection criteria based on
UV traces, a small variation in the position of the peak can have a large effect on the
volume collected particularly for steps where significant leading or tailing on elution
peaks may occur. Certain chromatography steps, for example, may be highly sensi-
tive to the pH and conductivity of the elution buffer. When considering a process at
scale which may use inline dilution for buffers, the control over pH and conductivity
is generally less precise than can be achieved at the laboratory scale. Different batches
of buffers can also influence the binding and elution profiles. Furthermore, when tech
4.4. Method 98
transfer activities are planned before the process limits evaluation validation studies
during Phase III clinical trials, most of the manufacturing data would be from lab-scale
or small-scale experiments. Predicting variability in eluate volumes at large scale from
data generated by small laboratory columns is complicated by several factors such as
differences in dispersion and retention volumes between the two scales of operation
(Hutchinson et al., 2009) as well as fluctuations in operating conditions (e.g. buffer pH
and conductivity). As a result, a value of ±50% in eluate volumes was considered to
reflect this uncertainty as a worst case scenario for most processes.
Table 4.1: Variable Distribution Ranges
Variable Min Most Likely Max
Product Titre -10% Base Case +10%
Elution Volumes -50% Base Case +50%
Filter Flux Rates -10% Base Case +10%
Step Yields
Chromatography Steps 83% 88% 93%
Virus Inactivation 98% 99% 100%
Ultrafiltration / Diafiltration 90% 95% 99%
Virus Retention Filtration 90% 95% 99%
4.4 Method
The database-driven discrete-event simulation tool described in Chapters 2 and 3 for
modelling the logistics and process economics of antibody process was used as the core
evaluation engine for this study. It was adapted to perform Monte Carlo simulations and
handle the larger datasets required so as to mimic the impact of process fluctuations on
the key outputs. A series of multivariate and visualisation analyses were then explored
to examine the stochastic simulation outputs. These are elaborated upon further in the
following sections.
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4.4.1 Database Configuration for the Monte Carlo Simulations
The simulation database was not originally designed to store the required inputs and
outputs from stochastic simulations. The data structure was modified to handle the
more complex datasets. Where before the values were stored as single constant values,
stochastic simulations require an ability to define distributions. In this chapter only
triangular distributions were used, but the new data structure was designed to allow
different distribution functions to be defined in the future.
In some cases, the distribution was not used to calculate the final sensitised value,
rather it was used to determine a multiplication factor. In turn, this factor was used to
modify a parameter which was only calculated during the simulation. In this instance
although the distribution was the same shape, the simulation needed to know that the
value generated must be used in a subsequent calculation. This method was used to
sensitise the filter flux rate. The final flux rate is dependent on filtration area and prod-
uct concentration, parameters which are only available after they have been calculated
during the simulation.
The solution was to use two fields in the database tables where the distributions
were to be defined. The fields were defined in addition to the existing data so as to
allow the simulation to be operated in deterministic mode without modification. The
first field was a numerical identifier which relates to the shape of the distribution. The
second field was a coded variable containing the parameters for the bounds of the distri-
bution. The value in the identifier field determined would function will be used by the
simulation and the coded variable stored the inputs to the function as a set of comma
separated variables.
This approach to capturing stochastic inputs enabled modifications to be made that
limited effect on the existing data structure whilst allowing for the maximum degree of
flexibility.
As well as defining a data structure for the input parameters, the results from
multiple iterations had to be stored. The existing database described in Chapters 2 and
3 stored a single set of results from each simulation across the archive tables off the
database. Each complete simulation was assigned a unique ID number such that the
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results from any one simulation could be collated at a later date. During Monte Carlo
simulations multiple result sets are generated for each simulation so a single field could
no longer be used to identify individual results. The solution was to add an additional
iteration ID field. The combination of simulation ID and iteration ID allowed any single
result set to be identified and analysed. By being able to separate and isolate individual
iterations from Monte Carlo result sets it was possible to carry out a more in-depth
analysis on the root causes of the outputs observed.
4.4.2 Stochastic Discrete-Event Simulation Engine
The discrete-event simulation engine described in Chapters 2 and 3 was configured to
run Monte Carlo simulation by tying a random number generator into new functions
which could generate the values within the distributions described in the database. This
is the simplest method of implementing Monte Carlo simulations but alternatives such
as Latin Hypercube Sampling (Helton and Davis, 2003) can be more efficient and result
in faster CPU times.
The key challenges were as follows:
• Enabling the simulation to identify where a parameter was sensitised.
• Importing and converting the coded variable into usable parameters.
• Generating the values within the defined distribution.
• Reconfiguring the functions which manage the input and output from the
database to handle the more complex datasets.
• Achieving the above without significant modifications to the existing simulation
structure.
The numerical identifier field was used to determine if a distribution should be
used. A value of 1 directs the simulation engine to use the original deterministic (point)
value. Values other than 1 correspond to different shapes of distribution and whether
the calculated value is to be used directly or as a multiplication factor. For example a
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value of 2 triggers a function to generate values within a triangular distribution using
equation 4.1.
x =

a +
√
U (b− a) (c− a) if U ≤
c− a
b− a

b−√(1− U) (b− a) (b− c) if U >
c− a
b− a
 (4.1)
where a = Minimum, b = Maximum, c = Mode, U = random number between
0-1.
In the above case, the values for the minimum, maximum and mode were retrieved
from the comma separated coded variable stored in the database. The random number
was provided by a random number generator built into the ExtendSim software.
4.4.3 Principal Component Analysis Method
Methods for principal component analysis have been widely documented. The method
used in this thesis was derived from Thornhill et al. (2006) and uses singular value de-
composition. The output data from the simulations were first transformed by mean cen-
tring and stored as a comma separated variable file which was then imported. The PCA
analysis methods were initially coded in Mathematica (See Appendix B) However, to
allow for a greater degree of automation the analysis was subsequently transferred to
SPSS Statistics (IBM Corp., NY).
The main aim of principal component analysis is to reduce the dimensionality of a
dataset whilst minimising the loss of information. It was first developed for use in the
behavioural sciences to determine a smaller number of behavioural traits from a large
number of behavioural observations. (Rummel, 1970)
The primary output of the analysis is a new data set where the original variables
have been replaced by principal components and the values for each variable are trans-
formed into scores within each principal component. The weighting of the original
variables within the principal components will determine how the scores relate back to
the original data. However, it can be said that the structure of the scores will represent
the structure of the original dataset and if successful, the structure will be evident in a
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lower dimension than the original data and thus easier to visualise. (Jackson, 1991)
Eigenvalues are used to determine which principal components are of key impor-
tance. Several methods are used to test for significance. (Valle et al., 1999; Zwick,
1986) The most common of these is to divide each eigenvalue by the mean of all eigen-
values and consider all principal components with an eigenvalue greater than 1 as sig-
nificant. The eigenvalues can also be plotted for each principal component, the result
is a scree plot as shown in Figure 4.4. Visual analysis of the scree plot may determine
that the average eigenvalue method is not suitable if the data is not highly correlated.
Instead a visual analysis of the scree is required to identify significant changes in gra-
dient. The ideal scree plot will consist of a small number of high value eigenvalues
followed by a sudden drop and a gradual tailing of the remaining eigenvalues. The
principal components before the drop are considered significant and those after have
less statistical value. (Cattell, 1966; Rozett, 1975)
Upon identification of the key principal components the scores from each compo-
nent can be analysed using cluster analysis. SPSS was used to assess the performance
of two clustering methods. These were hierarchical clustering, and k-means clustering.
Hierarchical clustering was used by Thornhill et al. (2006) with a data set of similar
complexity and structure and whilst various methods were used to improve the method,
hierarchical clustering was not able to satisfactorily elucidate the clusters within the
dataset generated in this analysis. An example dendrogram is shown in Appendix B.
Instead k-means clustering was used. The k-means clustering algorithm used in this
thesis was a function within SPSS.
SPSS was also used to generate graphical outputs in the form of scatter plot ma-
trices and parallel co-ordinate plots. Both methods were used to visualise the higher
dimensional datasets generated as part of this analysis and are discussed in more detail
throughout this chapter.
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4.5 Results
4.5.1 Case Study Aim
The case study looks at the first batch at scale. The process description used in Chapter
3 and detailed in Appendix A was combined with a hypothetical 10,000L (10K) facility.
The aim was to identify potential short term facility fit issues upon tech transfer and the
probability that they would be realised. In addition to facility fit issues, the case study
also highlights how the sensitivity of a process to uncertainty can change with respect
to facility design.
The simulation engine was configured to run Monte Carlo simulations. The re-
sults were first analysed to investigate potential facility fit issues. Modifications were
then made to the simulated process (referred to herein as the modified 10k Facility) to
improve facility fit and the Monte Carlo simulations were repeated with the improved
process. The complexity of each dataset was then reduced using principle component
analysis combined with clustering to reduce the dimensionality and eliminate noise
(Thornhill et al. 2006). The results were compared to assess the impact of the process
change.
The appropriate number of principal components were selected by a visual anal-
ysis of the eigenvalues plotted for each principal component. After selection of the
principal components, clusters in the dataset were identified using k-means clustering.
The clusters were generated by analysing the component scores. Finally, the input
parameter distributions for each cluster was visualised on vertical parallel co-ordinate
plots. The Monte Carlo simulation was run for 1000 iterations to generate the following
results.
4.5.2 Identifying Sub-optimal Facility Fit
4.5.2.1 Mass Throughput Profile
One of the key parameters of interest is the mass throughput of the facility (kg/batch).
In many cases the planning of manufacturing campaigns will be determined well in
advance of the first batches at scale, therefore it is important to have an accurate pre-
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diction of facility throughput early on in the development lifecycle. The stochastic
tool was used to predict the likelihood of product loss upon tech transfer using Monte
Carlo simulation, given the expected fluctuations in key performance indicators and
purification operating parameters indicated in Table 4.1.
Mass Throughput per Batch (Kg)
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Figure 4.1: Probability distributions for the throughput predicted from both the
base case (—–) and modified (- - -) 10K facility. The product titre at point of
harvest was 2g/L yielding 20kg of product from the reactor. (n=1000)
Figure 4.1 shows the predicted facility throughput for the processes running in
the 10k facility. Based on deterministic values, where only the most likely value is
considered for each parameter (e.g. product titre = 2 g/L, overall process yield = 55%)
and the 10,000L, fermenter scale, the predicted facility throughput would be calculated
at 11Kg/batch. The values predicted by the simulation fall well short of this value. A
very small proportion of batches meet the expected throughput. This is suggestive of
facility fit issues and prompts further investigation. As will be discussed later, upon
further investigation a facility fit issue was identified and corrected, resulting in the
modified 10K facility probability profile.
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Figure 4.2: Distribution of pool volumes for each step in the (a) base case and
(b) modified 10K facility data. Vertical bars are composed of a series of horizon-
tal dashes, each representing the pool volume from a single simulation iteration.
For clarity the distribution of values is shown by the histogram alongside each
bar. (n=1000)
4.5.2.2 Risk Hotspots for Facility Fit
The Monte Carlo simulation data for the pool volumes after each step in the purification
process were examined to identify the location of the equipment limitations causing the
facility fit issues. The simulation engine maintained a log of events that occurred dur-
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ing each simulation run. A section of this log was dedicated to vessel operations and an
error event was recorded when the amount of material exceeded the tank’s maximum
volume. Review of the log showed that an over-fill event occurred in two of the product
pool tanks in a number of runs. Since step yields and elution volumes are stochastic
variables some variability of pool volumes was expected. Figure 4.2 shows the distri-
bution of the pool volumes at each step. With the exception of the harvest pool which
in this simulation is defined as a fixed value entering the process, variation in the pool
volumes is evident. Figure 4.2(a) identifies the virus inactivation and anion exchange
chromatography pool volumes as risk hotspots.
The vertical histogram plotted alongside each column of data points shows a spike
in the distributions at 2500L for both of these tanks. This is due to the fact that the
largest volume that can be stored in these tanks was 2500L. Surplus volume was di-
verted to waste and the product was lost impacting throughput on a large number of
batches. This is a facility fit issue which must be addressed. The action was taken to
review tank allocation within the facility on which the simulation was based and addi-
tional tankage, not routinely available for product storage was identified. The specifica-
tion for these tanks were added to the database and therefore became an option for the
simulation engine. The simulation was re-run and with the additional tanks available,
the fit issue was resolved. This is shown in Figure 4.2(b).
With the tank volumes increased to handle the predicted pools, the volume of the
spike in the distribution was removed. The result of this modification would be to in-
crease the volume entering into subsequent steps and could also move the bottleneck
downstream. In this instance however sufficient capacity was installed and no addi-
tional tank issues were apparent. The impact of this facility fix on the facility through-
put can be seen in Figure 4.1 (dotted line), with the throughput closer to the predicted
value of 11kg/batch.
4.5.2.3 Probability of Meeting Demand
The data shown in Figure 4.1 can be used to generate probabilities of being able to
manufacture sufficient material within a number of batches and hence better manage
manufacturing risk. Figure 4.3 shows the probability of being able to meet varying
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Figure 4.3: Probability plot showing the probability of meeting a range of de-
mands within three batches using either the base case (—–) and modified (- - -)
10K facility. (n=1000)
demands within three batches. This illustrates that the minimum guaranteed demand
for the modified facility (Approx. 29kg) is almost double that of the base case facility
(Approx. 15kg). This is because not only is the throughput of the modified facility
higher, it is less variable.
4.5.3 Principal Component Analysis
In order to gain more insight into the performance of the process in the 10K, facility
principal component analysis was used to reduce the complexity of the dataset. The two
datasets from the base case and modified facility were analysed individually using the
same procedure. First the number of significant principal components was identified by
plotting their eigenvalues. This was followed by determining the number of significant
clusters and their membership. Finally, stacked parallel co-ordinate plots were created
to determine the combination of batch characteristics that led to product losses.
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Figure 4.4: Scree plots generated from the principal component analysis of the
(a) base case and (b) modified 10K facility data.
4.5.3.1 Principal Component Selection
The scree plot shown in Figure 4.4 was used to determine the number of significant
principal components. The average eigenvalue method, which defines significant com-
ponents as having eigenvalues greater than 1 is not suitable for these datasets as this
would include a number of principal components which add little value. Instead the
appropriate number of principal components was selected by a visual analysis of the
dataset. (Zwick, 1986; Cattell, 1966) In this case for the base case the first 5 princi-
pal components were selected and for the modified facility the first 6. In both cases
selection of any additional components added little to the integrity of the dataset.
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Figure 4.5: Clustered scatter matrices showing the score values for the first
three principal components generated by the PCA of the (a) base case and (b)
modified 10K facility data. k-means clustering was used on the first 5 principal
components, 3 are shown for clarity. (n=1000)
4.5.3.2 Cluster Identification
After selection of the principal components, hierarchical clustering was used to deter-
mine the number of significant clusters by visual inspection of the resultant dendro-
gram. For the base case facility data the dendrogram is shown in Figure 4.6. In this
instance the clusters were defined at an average distance between the clusters of 20
units. Further branching leads to less distinct clusters.
The method used for hierarchical clustering did not allow for the extraction of
cluster membership at specific average distances hence, k-means clustering was then
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Figure 4.6: Dendrogram generated from the hierarchical clustering of principal
component analysis of base case 10K facility data.
used to identify the cluster membership of the six distinct clusters. This method was
repeated for the modified facility which also identified 6 distinct clusters at a similar av-
erage distance. To aid visualisation, the key principal components were plotted against
each other on a scatter plot matrix (Figure 4.5). Each of the cells in the scatter plot
matrices shown in Figure 4.5 were generated by plotting the component scores from
each principal component against each other. For example, all the charts in the first
row show principal component 1 scores plotted against: themselves in column 1, prin-
cipal component 2 scores in column 2 and principal component 3 scores in column 3.
Since the plots on the diagonal are the principal components plotted against themselves
the data is represented as a histogram to show the distribution of the scores within each
principal component.
In addition to the scatter plot matrices the clusters identified by k-means clustering
are shown as different coloured points.
For example, the scatter plots in Figure 4.7(a) for PC3 vs. PC1 clearly indicate
the presence of two distinct and nonoverlapping clusters. Each of these clusters can
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be split into further non-overlapping clusters as indicated in Figure 4.7(a) as a result of
k-means clustering in higher dimensions. By allowing the clusters to be visualised in
the PCA score space, these scatter plots allow verification of the success of the k-means
clustering for these datasets. By carrying out the principle component analysis first we
have removed those parameters which have less influence on the structures within the
dataset thereby reducing noise and the dimensionality of the data.
(a)
Titre
AEX Cycles
Affinity Cycles
CEX Cycles
Affinity Elution Vol
CEX Elution Vol
AEX Elution Vol
Product Mass
Mass Loss
Batch Duration
Processing Time
Batch Cost
Cost of Goods
21.6 14.5 8.6 21.3 18.8 15.2
Cluster Membership (%)
(b)
Titre
AEX Cycles
Affinity Cycles
CEX Cycles
Affinity Elution Vol
CEX Elution Vol
AEX Elution Vol
Product Mass
Mass Loss
Batch Duration
Processing Time
Batch Cost
Cost of Goods
16.5 14.2 16.9 15.1 18.9 18.4
Cluster Membership (%)
Figure 4.7: Vertical parallel co-ordinate plot showing PCA clustered data for
the (a) base case and (b) modified 10K facility data. (n=1000)
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4.5.3.3 Parallel Co-ordinate Visualisation
Next, the clustered data was converted back to values which have more meaning. This
was done by separating the input dataset into the clusters identified by the k-means
algorithm and this time plotting the original variables instead of the component scores
on a series of stacked parallel co-ordinate plots. This data is shown in Figure 4.7.
Figure 4.7(a) shows the data from the base case 10K facility. Thirty parameters were
input into the PCA algorithm however only the parameters of interest are shown here.
For clarity each parameter is normalised between -1 and 1 such that they can be easily
compared. The result is a facility fingerprint. By comparing Figures 4.7(a) and (b) the
wider impact of changing the tank volume can be quickly assessed. However, it should
be noted that the magnitude of the distributions in the two sets of parallel coordinate
plots are different as they are normalised independently.
Each cluster of batches in Figure 4.7 has common characteristics that combined
lead to different outcomes such as high mass losses. For example, an examination of
cluster 4 in Figure 4.7(a) indicates that despite high titres, the cluster also exhibits high
cost of goods. This can be attributed to a high average level of mass loss that was
strongly linked to a high average elution volume on the affinity step.
Figures 4.7(a) and 4.7(b) can be compared together to understand how the facil-
ity fingerprint changes after the facility fix. Before the modification (Figure 4.7(a)),
all clusters of batches exhibit significant variance in product mass loss. After the fix
(Figure 4.7(b)), the variance in mass loss can be seen to be removed as indicated by
the pinch point formed across all clusters. Further comparison links this to the reduced
variability in the number of chromatography cycles (affinity, AEX and CEX). This
represents a significant improvement in the process schedules ability to absorb the un-
certainty. The number of cycles overall may be higher in the modified facility, however
they are more predictable with is often of greater importance.
4.6 Conclusions
This chapter illustrates the insights that can be gained by integrating stochastic simu-
lation data with advanced multivariate statistical techniques for predicting and under-
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standing facility fit issues upon tech transfer. The Monte Carlo data enabled a greater
degree of understanding of the impact of process fluctuations and subsequent facil-
ity modifications on the likelihood of meeting manufacturing targets. An early ap-
preciation of risk allows for the planning of risk avoidance strategies such as contin-
gency batches or process changes. The effect of the facility modification identified was
analysed in more detail with multivariate statistical analysis techniques that harnessed
principal component analysis, clustering algorithms and high dimensional visualisation
techniques combined to generate facility fingerprints. These allowed for rapid identi-
fication of process robustness and characteristics of clusters of batches that resulted in
product losses and hence suboptimal facility fit.
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Chapter 5
Validation
5.1 Introduction
This chapter discusses the regulatory aspects of pharmaceutical manufacture and fo-
cuses on the place of decision support tools in the validation of bioprocesses. This
chapter draws on guidance provided by the Food and Drug Administration and the In-
ternational Conference on Harmonisation of Technical Requirements for Registration
of Pharmaceuticals (ICH).
5.1.1 Quality by Design
“Currently, manufacturing process selection and development are usually based on en-
gineers knowledge and experience. Process simulation tools can help identify optimal
and efficient processes and facilitate process scale up from exhibit batches to commer-
cial manufacturing.” (Center for Drug Evaluation and Research, 2007)
The above quote is from a technical report published by the FDA outlining key
areas for consideration within the QbD framework for the development and approval
of generic drugs. Since this report was published the FDA has confirmed its stance
of the position of QbD within regulatory filings, by requiring that all submissions for
generic drugs made after January 2013 must demonstrate QbD principles have been
used. (Rosencrance, 2011)
Generic drug manufacture is the current area of focus for the FDA and other reg-
ulatory authorities as they attempt to provide legislation and guidance for what is still
an emerging area of the industry. It is therefore likely that this same guidance will be
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implemented for all submissions in the near future.
The traditional approach to quality management within drug manufacture is for
quality assurance oversight of a fixed manufacturing process and quality control release
testing of the finished product. Where the process deviates from the fixed process in-
process testing is used to justify the impact on product quality.
The move to QbD acts to ensure that the quality is built into the final product by
developing the process with an understanding of critical quality attributes and critical
process parameters. Manufacturer’s must therefore define these attributes and parame-
ters and the ranges of normal operation to form a QbD design space. In principle, with
the QbD framework, the emphasis on release testing is reduced as a process operating
within the design space will, by design, produce product of the required quality.
Quality by design (QbD) focuses on the robustness of a process design where vari-
ation is understood, accepted and managed. Simulation tools provide the potential to
investigate the effects of process variation and make design decisions accordingly. For
example for products where stability issues are critical, hold times may become critical
quality attributes. In this case simulation tools can be used to understand the varia-
tion in hold times that may be expected in a process as a result of resource constraints,
where the times exceed critical limits decisions can be made to alleviate bottlenecks.
Where resource utilisation changes for a process for example due to equipment failure
or supplier issues, simulations could be used throughout a process to determine the
effects and plan accordingly.
5.2 Conclusions
The future of process simulation may be routine use in in-online decision making,
simulating potential outcomes of scenarios before implementation and then changing
the process accordingly. This may eventually be seen as one way to adapt in a controlled
manor to the inherent variability of biological processes. An example would be to
adjust the harvest time of a reactor based on cell growth and productivity with a view
to optimise primary recovery operations; provide more favourable material to DSP or
to better fit the facility schedule.
The FDA and other regulatory authorities are pushing pharmaceutical manufac-
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turers to display a greater understanding of their processes. This includes the use of
statistical analysis when analysing process data and to demonstrate that a process is
operating consistently and in control. Primary to this are the analysis of process perfor-
mance qualification (PPQ) batches, also known as process validation series or consis-
tency lots. Although there is no binding recommendation as to the number of batches,
typically 3 or more are carried out. This presents a potential problem for pharmaceuti-
cal companies, as sound statistical analysis on a sample size of only 3 is difficult. One
solution regularly employed is to use data generated during process development to
increase the samples size and provide a more complete picture to the regulatory author-
ities. Process simulations could also be an important source of data and could provide
a potential wealth of useful information.
Whatever the future for decisional tools in bioprocessing, an insight into the de-
mands of computer systems validation may prove useful for the long term future proof-
ing of systems developed today and the selection of validatable platforms which do not
rely on Excel and similar third party tools my be pivotal in establishing a foothold in
the industry.
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Chapter 6
Conclusions and Future Work
6.1 Conclusions
The project sponsor was Lonza Biologics plc., as such the main focus of this project was
antibody manufacturing processes. Over the course of the EngD supervisors changed
and the project moved between different departments, this resulted in a shift in focus
which shaped the direction of the project.
The initial remit was to develop a simulation tool that could be used to assess fa-
cility fit of manufacturing processes and to provide a greater understanding of the lim-
itations of the manufacturing facilities currently in operation. This was set against the
backdrop of an environment where there have been large advances in upstream process-
ing (USP) technology with titres increasing from milligram to multi-gram quantities,
in the same timeframe there has been relatively limited progress being made in down
stream processing (DSP).
At the start of the project in 2005 a high titre was considered to be 2g/L, at the
end, 5 years later, industry is achieving 5g/L routinely and processes achieving titres
of close to 10g/L are already becoming a reality. In contrast the platform process in
DSP has remained largely unchanged. A large majority of processes can be described
by the 3 step platform, named because of the 3 chrome steps that form the backbone
of the process. Typically we see a protein A affinity step with two further column
polishing steps, virus inactivation and filtrations steps and a typically two ultrafiltration
diafiltation (UFDF) steps one for buffer exchange post protein A and one to transition
the product into it’s final formulation.
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Whilst there are a few variations, perhaps hydrophobic interaction chromatogra-
phy (HIC) in place of the final ion exchange step and more recently membrane based
chromatography, none of these truly represents a paradigm shift in manufacturing.
Based on this history, the central question for the first part of this thesis was, how
long will it be before a facility developed around the 3 step platform process becomes
bottlenecked? By this we mean at which point will the process not be able to reap the
rewards of the upstream process improvements? This techniques required to address
this question were discussed in chapter 3.
After the first two years the original project moved in a new direction as the su-
pervisor, who was based in DSP manufacturing, moved on from Lonza. The new su-
pervisor, now based in process and technology transfer, was more interested in how
process uncertainty would effect facility fit. Instead of investigating long term facility
fit the focus shifted to short term facility fit. The question now became; how will the
predicted process variation between batches within a campaign result in issues? This
formed the basis of chapter 4.
In order to answer these questions the need was identified for the development of
a flexible simulation framework with the capability of stochastic simulation. This took
the form of a discrete event simulation engine and a complimentary relational database.
The selection of software tools and the development of the framework was discussed
in chapter 2.
Often, the approach to simulation is to develop what is essentially an expert sys-
tem, a model which is designed around a single largely fixed process. This allows you
to design highly efficient and accurate simulations however, if there is a process change
the simulation must be rewritten or redeveloped, for example to account for a change
in scale. To address the first question, that of long term facility fit in an environment
of increasing titres, the technology of the platform process remains constant, and the
scale changes to accommodate the increasing upstream titres. To efficiently model the
problem, a simulation engine was designed to scale any given process within the lim-
itations of the facility. This required a new approach to the structure of discrete event
models. In this case the simulation was built using a novel router based structure that
was able to adapt to any process specified in the database. In addition an optimisation
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module was able to automatically scale the process using established rules of scale up
before feeding that process into the simulation.
Once the project moved into looking at short term facility fit, the simulation engine
was further developed to carry out Monte Carlo simulation. Now the process and scale
were fixed, but key parameters of the process were no longer defined as fixed values but
instead defined as triangular distributions. New functionality was developed to enable
the simulation engine to use a random number generator to randomly select values
from within distributions defined in the database rather than use the previously fixed
values. When running Monte Carlo simulations the simulation engine is connected to
a powerful database to facilitate the large datasets generated for each simulation run.
This means that it was not only possible to see the impact that uncertainty has on key
process variables such as cost time or product yield, it is also possible to investigate
circumstances which led to the output that is observed.
The enhanced datasets are however massive and complex and more sophisticated
statistical analysis is needed to determine the structure of the data. This led to the devel-
opment of a set of methods using principal component analysis to simplify the dataset
and clustering algorithms to identify key process types, the data are then presented us-
ing parallel co-ordinate plots to generate novel process fingerprint which can be used
to visualise process robustness. Comparison of these fingerprints can also be used to
assess the impact of process changes.
6.2 Future Work
This section outlines possible future directions for the research discussed in this thesis
to address shortcomings and to expand functionality.
6.2.1 Unit Operation Pallet
The simulation engine has the functionality to simulate those unit operations which
form part of a generic platform process for the purification of monoclonal antibodies.
At the time of development, these unit operations represented the standard. Newer tech-
nologies such as membrane chromatography are now seeing an increased use within
antibody manufacturing and they present different challenges for facility fit. New unit
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operation blocks will need to be constructed to assess these newer technologies. In
addition the unit operation pallet could be extended to cover those unit operations used
for the production of non-antibody products and include operations such as protein
refolding steps or conjugation reactions.
This project focused on whole process simulation and the unit operation models
themselves are only designed to perform mass balance, resource and scheduling cal-
culations. More complex models are available to simulate, for example the removal
of impurities, filtration flux decay rates or other factors relating to the performance
of steps which may be affected by those parameters which were sensitised within the
framework such as product concentration. The framework could serve as a basis to
link a number of the more advanced single unit operation models together to provide a
greater insight into the performance of steps and the effects of these model outputs on
the wider process.
6.2.2 Ancillary Processes
Ancillary activities are those which are required to support the process, but do not
directly interact with the product stream. This includes cleaning and sterilisation pro-
cesses and buffer prep. Taking the example of buffer prep, the simulation engine pro-
vides information on buffer quantities required and associated raw materials, however
buffer prep operations do not act to constrain the process schedule. This is because in
order to do this buffer prep would need to be predicted in advance of the requirement to
provide a realistic representation of how buffer prep activities are scheduled in a real fa-
cility. The pre-scheduler element of the simulation framework was initially developed
with this functionality in mind, however it could not be successfully implemented to
provide accurate enough predictions of the buffer schedule. Further work is needed to
build functionality to enable prediction of activities such as buffer prep, clean in place
and steam in place such that the impact of these steps can be included in the overall
facility fit assessment.
6.2.3 Continuous Processing
The simulation engine is focussed on batch processing. Continuos processing presents
a number of different challenges which cannot currently be addressed within the frame-
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work. Researchers at UCL have demonstrated that the framework can be expanded to
include the capability of continuos processing and this presents an interest avenue for
further investigation.(Pollock et al., 2013)
6.2.4 Optimisation Methods
The prescheduler module which is designed to determine optimum process configura-
tions based the availability of equipment and process variables used brute force optimi-
sation. This method was found to be acceptable with respect to processing times and the
robustness of determining optimum process configurations within the bounds of pro-
cessing time and costs. This method is however not scalable as the number of process
options increases exponential with the number of dimensions. More scalable methods
such as latin hypercube sampling or genetic algorithms will be required to maintain an
acceptable runtime should the optimisation challenges become more complex.
6.2.5 Automated Clustering
Two clustering methods were investigated hierarchical and k-means. Other clustering
methods exist and could be investigated further for the analysis of the data. The disad-
vantage of k-means clustering is that the algorithm requires that the number of clusters
be known prior to running the algorithm, in the case studies, hierarchical clustering was
therefore used first to determine the number of clusters which could then be fed into the
k-means algorithm. This method was not automated and required a manual analysis of
the hierarchical clustering data.
6.2.6 Graphical User Interface
Currently multiple applications are required to allow the user to interact with the sim-
ulation engine and the results generated. The development of a single graphical user
interface could greatly enhance the usability of the simulation framework. This is an
activity that would need to be completed to consider rolling out the framework for use
by industry.
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Appendix A
Base Case Process Description
A.1 Process Description
The tables in this appendix detail the base case process parameters used throughout this
thesis. The process is defined using scale independent process parameters such that the
same process can be investigated at a range of scales as required.
A.1.1 Protein A Chromatography (Bind and Elute)
Table A.1: Protein A Affinity Chromatography Specifica-
tions
Parameter Value
Principle Bind and Elute Affinity Chromatography
Resin Type Protein A Affinity
Max Resin Cycle Number 100
Packing Flow Rate (cm/h) 750
Operational Flow Rate (cm/h) 450
Expected Step Yield (%) 88
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Table A.2: Protein A Affinity Chromatography Operation
Parameter Value
Clean
Buffer Protein A Cleaning Buffer
Volume (CV) 3
Hold Time (h) 0.25
Frequency Immediately before each cycle.
Equilibration
Buffer Protein A Equilibration Buffer
Volume (CV) 5
Load
Dynamic Binding Capacity (g/L) 25
Volume (CV) Variable
Post Load Wash 1
Buffer Protein A Wash Buffer A
Volume (CV) 2
Post Load Wash 2
Buffer Protein A Wash Buffer B
Volume (CV) 6
Post Load Wash 3
Buffer Protein A Wash Buffer A
Volume (CV) 4
Elution
Buffer Protein A Elution Buffer
Elution Buffer Volume (CV) 5
Volume Collected (CV) 2
Strip
Buffer Protein A Strip Buffer
Volume (CV) 2
Regeneration
Continued on next page...
A.1. Process Description 124
Parameter (continued) Value (continued)
Buffer Protein A Cleaning Buffer
Volume (CV) 3
A.1.2 Low pH Virus Inactivation
Table A.3: Virus Inactivation
Parameter Value
Principle Virus inactivation through low pH hold.
Hold Time (h) 1
Acid Vol (ml/L) 16
Base Vol (ml/L) 42
Expected Step Yield (%) 100
A.1.3 Post Protein A Ultrafiltration/diafiltration
Table A.4: Post Protein A UFDF Specifications
Parameter Value
Principle Buffer exchange and product con-
centration using cross-flow filtra-
tion.
Pore Size (kDa) 30
DF Concentration (g/L) 30
Final Concentration (g/L) 25
Diafiltraiton Volumes 3
Continued on next page...
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Parameter (continued) Value (continued)
Diafiltration Buffer Anion Exchange Equilibration
Buffer
Ω1
1 -59.217
Ω2
1 253.33
Max Step Time (h) 6
Expected Step Yield 99%
A.1.4 Anion Exchange Chromatography (Flow Through)
Table A.5: Anion Exchange Chromatography Specifications
Parameter Value
Principle Product flows through column and
contaminants remain bound.
Resin Type Anion Exchange
Max Resin Cycle Number 50
Packing Flow Rate (cm/h) 700
Operational Flow Rate (cm/h) 450
Expected Step Yield 88%
Table A.6: Anion Exchange Chromatography Operation
Parameter Value
Clean
Buffer Anion Exchange Cleaning Buffer
Continued on next page...
1Ω1 and Ω2 are experimentally derived parameters to estimate flux at various concentrations.
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Parameter (continued) Value (continued)
Volume (CV) 3
Hold Time (h) 1
Frequency Immediately before each cycle.
Equilibration
Buffer Anion Exchange Equilibration Buffer
Volume (CV) 5
Load
Dynamic Binding Capacity (g/L) 50
Volume (CV) Variable
Volume Collected (Load Vols) 3
Post Load Wash 1
Buffer Anion Exchange Equilibration Buffer
Volume (CV) 8
Post Load Wash 2
Buffer Anion Exchange Wash Buffer
Volume (CV) 2
Regeneration
Buffer Cation Exchange Cleaning Buffer
Volume (CV) 3
A.1.5 Post Anion Exchange Ultrafiltration
Table A.7: Post Anion Exchange Chromatography UFDF
Specifications
Parameter Value
Principle Product concentration using cross-
flow filtration.
Continued on next page...
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Parameter (continued) Value (continued)
Pore Size (kDa) 30
Final Concentration (g/L) 25
Ω1
2 -59.217
Ω2
2 253.33
Max Step Time (h) 6
Expected Step Yield (%) 99
A.1.6 Cation Exchange Chromatography (Bind and Elute)
Table A.8: Cation Exchange Chromatography Specifications
Parameter Value
Principle Bind and elute cation exchange chromatography.
Resin Type Cation Exchange Resin
Max Resin Cycle Number 100
Packing Flow Rate (cm/h) 200
Operational Flow Rate (cm/h) 140
Expected Step Yield (%) 88
Table A.9: Cation Exchange Chromatography Operation
Parameter Value
Clean
Buffer Cation Exchange Cleaning Buffer
Volume (CV) 3
Hold Time (h) 1
Continued on next page...
2Ω1 and Ω2 are experimentally derived parameters to estimate flux at various concentrations.
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Parameter (continued) Value (continued)
Frequency Immediately before each cycle.
Equilibration
Buffer Cation Exchange Equilibration Buffer
Volume (CV) 5
Load
Dynamic Binding Capacity (g/L) 15
Volume (CV) Variable
Post Load Wash 1
Buffer Cation Exchange Equilibration Buffer
Volume (CV) 2
Elution
Buffer Cation Exchange Elution Buffer
Elution Buffer Volume (CV) 5
Volume Collected (CV) 2.5
Strip
Buffer Cation Exchange Strip Buffer
Volume (CV) 2
Regeneration
Buffer Cation Exchange Cleaning Buffer
Volume (CV) 3
A.1.7 Virus Reduction Filtration
Table A.10: Virus Reduction Filtration
Parameter Value
Principle Nanofiltration used to remove virus particles.
Filter Type 20nm Virus Reduction Filter
Continued on next page...
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Parameter (continued) Value (continued)
Flush Buffer VRF Flush Buffer
Flush Volume (L/m2) 8
Vmax (L/m2) 4778
Flux Rate (LMH) 48
Max Processing Time (h) 6
Expected Step Yield (%) 99
A.1.8 Final UFDF
Table A.11: Final UFDF Specifications
Parameter Value
Principle Buffer exchange and product con-
centration using cross-flow filtra-
tion.
Pore Size (kDa) 30
DF Concentration (g/L) 35
Final Concentration (g/L) 38
Diafiltraiton Volumes 10
Diafiltration Buffer Final formulation buffer
Ω1
3 -48.47
Ω2
3 253.33
Max Step Time (h) 6
Expected Step Yield (%) 99
3Ω1 and Ω2 are experimentally derived parameters to estimate flux at various concentrations.
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A.2 Key Costs
Table A.12: Key Process Costs
Item Cost
Chromatography Resins
Protein A £8000/L
Anion Exchange £800/L
Cation Exchange £400/L
Filters
30kDa Membrane £800/m2
Virus Reduction Filter £1700/m2
Disposable Bags
500L Bag £450
200L Bag £300
100L Bag £350
50L Bag £50
Other
Labour £30/h
131
Appendix B
Multivariate Statistical Analysis
B.1 Mathematica Code for PCA
The following code was used to implement the principal component method in Mathe-
matica.
a = I mp or t [ ” PCAMatr ixdataS . t x t ” , ” Tab le ” ] ; (* Im po r t d a t a from t e x t f i l e i n t o a * )
{u , d , v} = S i n g u l a r V a l u e D e c o m p o s i t i o n [a ] ; (* Perfom SVD on a , e x p o r t t o u , d , v * )
T = u .d ; ( * M u l i t p l y m a t r i x u by d *)
Wt = T r a n s p o s e [v ] ; (* T r a n s p o s e Ma t r i x v * )
Scores = T r a n s p o s e [T ] ; (* T r a n s p o s e m a t r i x T*)
Eigens = E i g e n v a l u e s [ T r a n s p o s e [a ] . a ] ; (* D e t e r m i n e s Eigen v a l u e s * )
NormEigens = Eigens / Mean [Eigens ] (* Mean c e n t r e E i g e n v a l u e s * )
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